{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:20:23Z","timestamp":1795112423608,"version":"4.10.3"},"reference-count":781,"publisher":"BMJ","issue":"Suppl 2","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the BSG IBD section to update its guidelines, last revised in 2019. These updated guidelines aim to complement the IBD standards and promote the use of the national primary care diagnostic pathway for lower gastrointestinal symptoms to enhance diagnostic accuracy and timeliness. Formulated through a systematic and transparent process, this document reflects a consensus of best practices based on current evidence. The guideline, while developed primarily for the UK, is structured to support IBD management internationally. It is endorsed by the BSG executive board and CSSC without external commercial funding, with involvement primarily supported through professional roles in public institutions and the National Health Service (NHS). Methodological revisions since the prior guidelines have enhanced rigor in technical review and development, with methodology details published independently following peer review. In developing the recommendations, 89 clinical experts and stakeholders participated in an online survey, identifying primary outcomes, such as clinical and endoscopic remission, as well as adverse event metrics, all stratified by clinically relevant effect sizes. These guidelines are intended to support clinical decision-making but are not prescriptive, recognizing that individual clinical scenarios may warrant tailored approaches. Further research may inform future revisions as new evidence emerges.<\/jats:p>","DOI":"10.1136\/gutjnl-2024-334395","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T14:40:50Z","timestamp":1751985650000},"page":"s1-s101","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":201,"title":["British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025"],"prefix":"10.1136","volume":"74","clinical-trial-number":[{"clinical-trial-number":"nct02770040","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04925973","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Gordon W","family":"Moran","sequence":"first","affiliation":[{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Central Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Sinopoulou","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Central Lancashire, Preston, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shellie J","family":"Radford","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-5134","authenticated-orcid":false,"given":"Ana-Maria","family":"Darie","sequence":"additional","affiliation":[{"name":"Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-3237","authenticated-orcid":false,"given":"Sudheer Kumar","family":"Vuyyuru","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6340-8244","authenticated-orcid":false,"given":"Laith","family":"Alrubaiy","sequence":"additional","affiliation":[{"name":"Swansea University Faculty of Medicine Health and Life Science, Swansea, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naila","family":"Arebi","sequence":"additional","affiliation":[{"name":"Department of Metabolism, Digestion and Reproduction, St Mark\u2019s the National Bowel Hospital and Academic Institute, London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Blackwell","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, Western General Hospital, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Butler","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology, and Gastroenterology, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thean","family":"Chew","sequence":"additional","affiliation":[{"name":"Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Colwill","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cooney","sequence":"additional","affiliation":[{"name":"St George\u2019s University Hospitals NHS Foundation Trust, London, UK"},{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2406-161X","authenticated-orcid":false,"given":"Gabriele","family":"De Marco","sequence":"additional","affiliation":[{"name":"University of Birmingham, Birmingham, UK"},{"name":"National Institute for Healthcare Research at Leeds Teaching Hospitals NHS Trust, Leeds Biomedical Research Centre, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Din","sequence":"additional","affiliation":[{"name":"University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahida","family":"Din","sequence":"additional","affiliation":[{"name":"University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Feakins","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Western General Hospital, Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"Department of Cellular Pathology, Royal Free London NHS Foundation Trust, London, London, UK"},{"name":"Department of Paediatrics, Norfolk and Norwich University Hospital NHS Trust, Norwich, Norfolk, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Gordon","sequence":"additional","affiliation":[{"name":"Jenny Lind Children\u2019s Hospital, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3944-6646","authenticated-orcid":false,"given":"Richard","family":"Hansen","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford, Oxfordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaartje B","family":"Kok","sequence":"additional","affiliation":[{"name":"15 Division of Respiratory Medicine and Gastroenterology, School of Medicine, University of Dundee, Dundee, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-3173","authenticated-orcid":false,"given":"Aditi","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Barts Health NHS Trust, Royal London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-4956","authenticated-orcid":false,"given":"Christopher A","family":"Lamb","sequence":"additional","affiliation":[{"name":"Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK"},{"name":"Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Limdi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK"},{"name":"Northern Care Alliance NHS Foundation Trust, Salford, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Liu","sequence":"additional","affiliation":[{"name":"The University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-1765","authenticated-orcid":false,"given":"Maurice B","family":"Loughrey","sequence":"additional","affiliation":[{"name":"Fairfield General Hospital, Bury, Manchester, UK"},{"name":"Department of Cellular Pathology, Belfast Health and Social Care Trust, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"McGonagle","sequence":"additional","affiliation":[{"name":"Centre for Public Health and Patrick G. Johnston for Cancer Research, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4864-2208","authenticated-orcid":false,"given":"Polychronis","family":"Pavlidis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospitals NHS Foundation Trust, London, London, UK"},{"name":"IBD Service, Department of Gastroenterology, King\u2019s College Hospital, London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Selinger","sequence":"additional","affiliation":[{"name":"King\u2019s College London School of Immunology & Microbial Sciences, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Shale","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Nottingham University Hospitals NHS Trust, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1568-3978","authenticated-orcid":false,"given":"Philip J","family":"Smith","sequence":"additional","affiliation":[{"name":"Leeds Teaching Hospitals NHS Trust, Leeds, UK"},{"name":"Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedhar","family":"Subramanian","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A","family":"Taylor","sequence":"additional","affiliation":[{"name":"Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1551-9174","authenticated-orcid":false,"given":"Gloria Shwe Zin","family":"Tun","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-3357","authenticated-orcid":false,"given":"Ajay Mark","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Newton A C S","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases, Kettering General Hospital NHS Foundation Trust, Kettering, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2026032503500973000_74.Suppl_2.s1.1","unstructured":"The hidden cost and a vision for change Crohn\u2019s and colitis care in the UK acknowledgements IBD UK board members and key contributors. 2021."},{"key":"2026032503500973000_74.Suppl_2.s1.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2022-001067","article-title":"BSG 2024 IBD guidelines protocol (standard operating procedures)","volume":"10","author":"Darie","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.3","doi-asserted-by":"crossref","unstructured":"Gordon M , Shaban N , Sinopoulou V , et al . n.d. Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions. Inflamm Bowel Dis. doi:10.1093\/ibd\/izaf085","DOI":"10.1093\/ibd\/izaf085"},{"key":"2026032503500973000_74.Suppl_2.s1.4","unstructured":"Sch\u00fcnemann H , Bro\u017cek J , Guyatt G . The GRADE handbook. UK: Cochrane Collaboration London, 2013."},{"key":"2026032503500973000_74.Suppl_2.s1.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7341.827"},{"key":"2026032503500973000_74.Suppl_2.s1.6","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2026032503500973000_74.Suppl_2.s1.7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/jgh3.12268","article-title":"Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge","volume":"4","author":"Rajagopalan","year":"2020","journal-title":"JGH Open"},{"key":"2026032503500973000_74.Suppl_2.s1.8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318484"},{"key":"2026032503500973000_74.Suppl_2.s1.9","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21493"},{"key":"2026032503500973000_74.Suppl_2.s1.10","doi-asserted-by":"crossref","first-page":"15374","DOI":"10.3748\/wjg.v20.i41.15374","article-title":"Performance of the Montreal classification for inflammatory bowel diseases","volume":"20","author":"Spekhorst","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.11","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.177"},{"key":"2026032503500973000_74.Suppl_2.s1.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-005-0160-3"},{"key":"2026032503500973000_74.Suppl_2.s1.13","doi-asserted-by":"publisher","DOI":"10.1159\/000104731"},{"key":"2026032503500973000_74.Suppl_2.s1.14","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.038505"},{"key":"2026032503500973000_74.Suppl_2.s1.15","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076"},{"key":"2026032503500973000_74.Suppl_2.s1.16","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90054-x"},{"key":"2026032503500973000_74.Suppl_2.s1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.016"},{"key":"2026032503500973000_74.Suppl_2.s1.18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/00365529609004876","article-title":"Changes in extent of ulcerative colitis: a study on the course and prognostic factors","volume":"31","author":"Langholz","year":"1996","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.19","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000225339.91484.fc"},{"key":"2026032503500973000_74.Suppl_2.s1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603"},{"key":"2026032503500973000_74.Suppl_2.s1.21","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"key":"2026032503500973000_74.Suppl_2.s1.22","article-title":"Cannabis for the treatment of ulcerative colitis","volume":"11","author":"Kafil","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300486"},{"key":"2026032503500973000_74.Suppl_2.s1.24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.07.024"},{"key":"2026032503500973000_74.Suppl_2.s1.25","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv111"},{"key":"2026032503500973000_74.Suppl_2.s1.26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5946\/ce.2018.042","article-title":"Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease","volume":"52","author":"Lee","year":"2019","journal-title":"Clin Endosc"},{"key":"2026032503500973000_74.Suppl_2.s1.27","unstructured":"Vashist NM , Samaan M , Mosli MH . Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev 2018."},{"key":"2026032503500973000_74.Suppl_2.s1.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.06.001"},{"key":"2026032503500973000_74.Suppl_2.s1.29","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000164024.10848.0a"},{"key":"2026032503500973000_74.Suppl_2.s1.30","first-page":"S576","article-title":"Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data","volume":"11","author":"Bojic","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.31","doi-asserted-by":"crossref","unstructured":"James E , Morris G , Gaurav BN , et al . British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. Gut 2025. doi:10.1136\/gutjnl-2025-335023","DOI":"10.1136\/gutjnl-2025-335023"},{"key":"2026032503500973000_74.Suppl_2.s1.32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","article-title":"Assessing Severity of Disease in Patients with Ulcerative Colitis","volume":"49","author":"Pabla","year":"2020","journal-title":"Gastroenterol Clin North Am"},{"key":"2026032503500973000_74.Suppl_2.s1.33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312307"},{"key":"2026032503500973000_74.Suppl_2.s1.34","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.cgh.2020.08.019","article-title":"Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis","volume":"19","author":"Stevens","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.35","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cgh.2022.07.027","article-title":"Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis","volume":"21","author":"Dulai","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ecco-jcc\/jjy184","article-title":"Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis","volume":"13","author":"Walsh","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izaa163","article-title":"Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients","volume":"27","author":"Cannatelli","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ibd\/izac095","article-title":"Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission","volume":"29","author":"Kawashima","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.39","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.120"},{"key":"2026032503500973000_74.Suppl_2.s1.40","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad108"},{"key":"2026032503500973000_74.Suppl_2.s1.41","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ecco-jcc\/jjad071","article-title":"Early Intestinal Ultrasound Predicts Long-Term Endoscopic Response to Biologics in Ulcerative Colitis","volume":"17","author":"Allocca","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ecco-jcc\/jjaa151","article-title":"Point-of-Care Ultrasound in Inflammatory Bowel Disease","volume":"15","author":"Allocca","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.43","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/ecco-jcc\/jjab002","article-title":"Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index","volume":"15","author":"Bots","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ibd\/izad043","article-title":"Composite Assessment Using Intestinal Ultrasound and Calprotectin Is Accurate in Predicting Histological Activity in Ulcerative Colitis: A Cohort Study","volume":"30","author":"Goodsall","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.45","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2021-102065"},{"key":"2026032503500973000_74.Suppl_2.s1.46","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.082909"},{"key":"2026032503500973000_74.Suppl_2.s1.47","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200002000-00002"},{"key":"2026032503500973000_74.Suppl_2.s1.48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A SIMPLE INDEX OF CROHN\u2019S-DISEASE ACTIVITY","volume":"315","author":"Harvey","year":"1980","journal-title":"The Lancet"},{"key":"2026032503500973000_74.Suppl_2.s1.49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a Crohn\u2019s Disease Activity Index","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.50","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn\u2019s Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.51","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.31072"},{"key":"2026032503500973000_74.Suppl_2.s1.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905063401804"},{"key":"2026032503500973000_74.Suppl_2.s1.53","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000215091.77492.2a"},{"key":"2026032503500973000_74.Suppl_2.s1.54","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2005.073"},{"key":"2026032503500973000_74.Suppl_2.s1.55","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10102203","article-title":"Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis","volume":"10","author":"Bromke","year":"2021","journal-title":"J Clin Med"},{"key":"2026032503500973000_74.Suppl_2.s1.56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12876-020-1183-x","article-title":"Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn\u2019s disease","volume":"20","author":"E Penna","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.57","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12031206","article-title":"Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis","volume":"12","author":"Shi","year":"2023","journal-title":"J Clin Med"},{"key":"2026032503500973000_74.Suppl_2.s1.58","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12092226","article-title":"Fecal Calprotectin for Small Bowel Crohn\u2019s Disease: Is It a Cutoff Issue?","volume":"12","author":"Romero-Mascarell","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"2026032503500973000_74.Suppl_2.s1.59","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/ibd\/izaa269","article-title":"Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn\u2019s Disease Regardless of Disease Location","volume":"27","author":"Buisson","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.60","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5217\/ir.2018.00114","article-title":"Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn\u2019s disease?: a systematic review","volume":"17","author":"Simon","year":"2019","journal-title":"Intest Res"},{"key":"2026032503500973000_74.Suppl_2.s1.61","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jgh3.12068","article-title":"Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn\u2019s disease activity","volume":"2","author":"Zittan","year":"2018","journal-title":"JGH Open"},{"key":"2026032503500973000_74.Suppl_2.s1.62","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14950"},{"key":"2026032503500973000_74.Suppl_2.s1.63","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2016-100686"},{"key":"2026032503500973000_74.Suppl_2.s1.64","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.cgh.2019.02.017","article-title":"Association Between Level of Fecal Calprotectin and Progression of Crohn\u2019s Disease","volume":"17","author":"Kennedy","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.65","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1077445"},{"key":"2026032503500973000_74.Suppl_2.s1.66","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJY113"},{"key":"2026032503500973000_74.Suppl_2.s1.67","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1391855"},{"key":"2026032503500973000_74.Suppl_2.s1.68","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1111\/jgh.16007","article-title":"The diagnostic yield of pan-enteric capsule endoscopy in inflammatory bowel disease: A systematic review and meta-analysis","volume":"37","author":"Tamilarasan","year":"2022","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.69","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5009\/gnl16015","article-title":"Effectiveness of Capsule Endoscopy Compared with Other Diagnostic Modalities in Patients with Small Bowel Crohn\u2019s Disease: A Meta-Analysis","volume":"11","author":"Choi","year":"2017","journal-title":"Gut Liver"},{"key":"2026032503500973000_74.Suppl_2.s1.70","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.dld.2017.04.013","article-title":"Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn\u2019s disease: Systematic review and meta-analysis","volume":"49","author":"Kopylov","year":"2017","journal-title":"Dig Liver Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ibd\/izz083","article-title":"Capsule Retention in Crohn\u2019s Disease: A Meta-analysis","volume":"26","author":"Pasha","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2011.03.1239"},{"key":"2026032503500973000_74.Suppl_2.s1.73","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.008"},{"key":"2026032503500973000_74.Suppl_2.s1.74","doi-asserted-by":"crossref","first-page":"8999","DOI":"10.3748\/wjg.v22.i40.8999","article-title":"Systematic review: Safety of balloon assisted enteroscopy in Crohn\u2019s disease","volume":"22","author":"Arulanandan","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.75","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3748\/wjg.v22.i7.2165","article-title":"Diagnostic imaging and radiation exposure in inflammatory bowel disease","volume":"22","author":"Zakeri","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.76","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.151415"},{"key":"2026032503500973000_74.Suppl_2.s1.77","first-page":"385","article-title":"Radiation exposure in Crohn\u2019s disease patients","volume":"94","author":"Bousorra","year":"2016","journal-title":"Tunis Med"},{"key":"2026032503500973000_74.Suppl_2.s1.78","unstructured":"Miles A , Bhatnagar G , Halligan S . Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn\u2019S disease. 2018."},{"key":"2026032503500973000_74.Suppl_2.s1.79","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.03.051"},{"key":"2026032503500973000_74.Suppl_2.s1.80","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.acra.2017.04.013","article-title":"A Diagnostic Accuracy Meta-analysis of CT and MRI for the Evaluation of Small Bowel Crohn Disease","volume":"24","author":"Liu","year":"2017","journal-title":"Acad Radiol"},{"key":"2026032503500973000_74.Suppl_2.s1.81","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2471070611"},{"key":"2026032503500973000_74.Suppl_2.s1.82","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/MIB.0000000000000727","article-title":"Medical Imaging in Small Bowel Crohn\u2019s Disease-Computer Tomography Enterography, Magnetic Resonance Enterography, and Ultrasound: \u201cWhich One Is the Best for What?\u201d","volume":"22","author":"Greenup","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.83","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30161-4"},{"key":"2026032503500973000_74.Suppl_2.s1.84","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00330-018-5661-2","article-title":"Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn\u2019s disease: patient acceptability and perceived burden","volume":"29","author":"Miles","year":"2019","journal-title":"Eur Radiol"},{"key":"2026032503500973000_74.Suppl_2.s1.85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04710.x"},{"key":"2026032503500973000_74.Suppl_2.s1.86","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.260"},{"key":"2026032503500973000_74.Suppl_2.s1.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.06.008"},{"key":"2026032503500973000_74.Suppl_2.s1.88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03556.x"},{"key":"2026032503500973000_74.Suppl_2.s1.89","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.03.039"},{"key":"2026032503500973000_74.Suppl_2.s1.90","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/apt.15190","article-title":"One-year clinical outcomes with biologics in Crohn\u2019s disease: transmural healing compared with mucosal or no healing","volume":"49","author":"Castiglione","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.91","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/ecco-jcc\/jjae042","article-title":"Magnetic Resonance Enterography and Intestinal Ultrasound for the Assessment and Monitoring of Crohn\u2019s Disease","volume":"18","author":"Kumar","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.92","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2468-1253(17)30248-0","article-title":"Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn\u2019s disease: a randomised controlled, open-label, multicentre trial","volume":"2","author":"Ponsioen","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.93","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ecco-jcc\/jjy055","article-title":"The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn\u2019s Disease","volume":"12","author":"Sands","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.94","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/jgh.12803","article-title":"Predictive value of early restoration of quality of life in Crohn\u2019s disease patients receiving antitumor necrosis factor agents","volume":"30","author":"Herrera-deGuise","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.95","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1021762"},{"key":"2026032503500973000_74.Suppl_2.s1.96","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-012-2072-0"},{"key":"2026032503500973000_74.Suppl_2.s1.97","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jgh.13866","article-title":"Oral and upper gastrointestinal Crohn\u2019s disease","volume":"33","author":"Laube","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.98","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/00365521.2019.1656776","article-title":"Clinical significance of endoscopic findings in the upper gastrointestinal tract in Crohn\u2019s disease","volume":"54","author":"D\u0105bkowski","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.99","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000000239"},{"key":"2026032503500973000_74.Suppl_2.s1.100","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/ecco-jcc\/jjab011","article-title":"Ecco topical review Optimising reporting in surgery, Endoscopy, and Histopathology: collaboration between s-Ecco, Educom, H-Ecco","volume":"15","author":"Adamina","year":"2021","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.101","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ecco-jcc\/jjab141","article-title":"ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease","volume":"16","author":"Feakins","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.102","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAD142"},{"key":"2026032503500973000_74.Suppl_2.s1.103","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/ecco-jcc\/jjaa110","article-title":"ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.104","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac006"},{"key":"2026032503500973000_74.Suppl_2.s1.105","doi-asserted-by":"crossref","unstructured":"Sinopoulou V , Nigam GB , Gordon M , et al . Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2024. doi:10.1016\/j.cgh.2024.11.008","DOI":"10.1016\/j.cgh.2024.11.008"},{"key":"2026032503500973000_74.Suppl_2.s1.106","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199808000-00008"},{"key":"2026032503500973000_74.Suppl_2.s1.107","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01533.x"},{"key":"2026032503500973000_74.Suppl_2.s1.108","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.2.174"},{"key":"2026032503500973000_74.Suppl_2.s1.109","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.12.1514"},{"key":"2026032503500973000_74.Suppl_2.s1.110","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2013-201885"},{"key":"2026032503500973000_74.Suppl_2.s1.111","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.045336"},{"key":"2026032503500973000_74.Suppl_2.s1.112","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2002.01416.x"},{"key":"2026032503500973000_74.Suppl_2.s1.113","doi-asserted-by":"publisher","DOI":"10.1053\/j.sempedsurg.2007.04.005"},{"key":"2026032503500973000_74.Suppl_2.s1.114","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200211000-00006"},{"key":"2026032503500973000_74.Suppl_2.s1.115","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa036"},{"key":"2026032503500973000_74.Suppl_2.s1.116","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198911000-00008"},{"key":"2026032503500973000_74.Suppl_2.s1.117","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0016-5085(84)90595-X","article-title":"Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease","volume":"86","author":"Surawicz","year":"1984","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.118","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/BF02087429","article-title":"\u201cNonspecific\u201d erosions and ulcers of the colonic mucosa","volume":"39","author":"Rubio","year":"1994","journal-title":"Dig Dis Sci"},{"key":"2026032503500973000_74.Suppl_2.s1.119","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.001"},{"key":"2026032503500973000_74.Suppl_2.s1.120","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.3.404"},{"key":"2026032503500973000_74.Suppl_2.s1.121","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.4979.1315"},{"key":"2026032503500973000_74.Suppl_2.s1.122","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.5.669"},{"key":"2026032503500973000_74.Suppl_2.s1.123","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310393"},{"key":"2026032503500973000_74.Suppl_2.s1.124","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa010"},{"key":"2026032503500973000_74.Suppl_2.s1.125","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/ecco-jcc\/jjz123","article-title":"Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.126","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03835.x"},{"key":"2026032503500973000_74.Suppl_2.s1.127","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000155"},{"key":"2026032503500973000_74.Suppl_2.s1.128","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.08.011"},{"key":"2026032503500973000_74.Suppl_2.s1.129","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-008-1290-5"},{"key":"2026032503500973000_74.Suppl_2.s1.130","doi-asserted-by":"crossref","unstructured":"Feakins RM . Transmural histology scores in stricturing Crohn\u2019S disease: seeking to build precision on uncertain foundations. Oxford University Press UK, 2020:721\u20133.","DOI":"10.1093\/ecco-jcc\/jjaa008"},{"key":"2026032503500973000_74.Suppl_2.s1.131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1751-2980.12937","article-title":"Histological scores in inflammatory bowel disease","volume":"22","author":"Neri","year":"2021","journal-title":"J Dig Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.132","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/apt.16248","article-title":"An expert consensus to standardise the assessment of histological disease activity in Crohn\u2019s disease clinical trials","volume":"53","author":"Almradi","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.133","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.giec.2019.02.010","article-title":"The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet?","volume":"29","author":"Salem","year":"2019","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"2026032503500973000_74.Suppl_2.s1.134","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)70476-7"},{"key":"2026032503500973000_74.Suppl_2.s1.135","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1053\/j.gastro.2019.06.037","article-title":"Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn\u2019s Disease","volume":"157","author":"Li","year":"2019","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.136","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/apt.15250","article-title":"Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn\u2019s disease","volume":"49","author":"Novak","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.137","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn\u2019s Disease","volume":"157","author":"L\u00f6wenberg","year":"2019","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.138","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-07338-x","article-title":"Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study","volume":"7","author":"Villanacci","year":"2017","journal-title":"Sci Rep"},{"key":"2026032503500973000_74.Suppl_2.s1.139","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: a single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.140","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.418"},{"key":"2026032503500973000_74.Suppl_2.s1.141","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309598"},{"key":"2026032503500973000_74.Suppl_2.s1.142","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e31819ad456"},{"key":"2026032503500973000_74.Suppl_2.s1.143","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21268"},{"key":"2026032503500973000_74.Suppl_2.s1.144","doi-asserted-by":"publisher","DOI":"10.1159\/000320415"},{"key":"2026032503500973000_74.Suppl_2.s1.145","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2468-1253(17)30252-2","article-title":"Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study","volume":"2","author":"Hyams","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.146","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/DCR.0b013e3181e751df","article-title":"Histopathology predictors of medically refractory ulcerative colitis","volume":"53","author":"Melson","year":"2010","journal-title":"Dis Colon Rectum"},{"key":"2026032503500973000_74.Suppl_2.s1.147","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MCG.0000000000000507","article-title":"Clinical Implications of Histologic Abnormalities in Ileocolonic Biopsies of Patients With Crohn\u2019s Disease in Remission","volume":"51","author":"Brennan","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.148","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.cgh.2019.11.056","article-title":"Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn\u2019s Disease than Endoscopic Healing","volume":"18","author":"Christensen","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.149","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ibd\/izaa301","article-title":"Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission","volume":"27","author":"Yoon","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.150","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.04.012"},{"key":"2026032503500973000_74.Suppl_2.s1.151","first-page":"e407","article-title":"The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis","volume":"28","author":"Alves","year":"2022","journal-title":"JCR: Journal of Clinical Rheumatology"},{"key":"2026032503500973000_74.Suppl_2.s1.152","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.153","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"2026032503500973000_74.Suppl_2.s1.154","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/apt.16952","article-title":"Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management","volume":"56","author":"Fehily","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.155","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02050.x"},{"key":"2026032503500973000_74.Suppl_2.s1.156","first-page":"770","article-title":"Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis","volume":"35","author":"Greenberg","year":"2008","journal-title":"J Rheumatol"},{"key":"2026032503500973000_74.Suppl_2.s1.157","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2010.12.020"},{"key":"2026032503500973000_74.Suppl_2.s1.158","first-page":"776","article-title":"Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population","volume":"35","author":"Ponce de Leon","year":"2008","journal-title":"J Rheumatol"},{"key":"2026032503500973000_74.Suppl_2.s1.159","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/jpm12030507","article-title":"Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"12","author":"Park","year":"2022","journal-title":"JPM"},{"key":"2026032503500973000_74.Suppl_2.s1.160","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.09.011"},{"key":"2026032503500973000_74.Suppl_2.s1.161","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-86053-0","article-title":"Low-dose steroids are associated with indeterminate QuantiFERON-TB Gold In-Tube assay results in immunocompetent children","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"key":"2026032503500973000_74.Suppl_2.s1.162","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-310870"},{"key":"2026032503500973000_74.Suppl_2.s1.163","doi-asserted-by":"crossref","unstructured":"Dobler CC . Biologic agents and tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections 2017;623\u201335. doi:10.1128\/9781555819866.ch37","DOI":"10.1128\/9781555819866.ch37"},{"key":"2026032503500973000_74.Suppl_2.s1.164","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/apt.14933","article-title":"Impact of Epstein\u2010Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease","volume":"48","author":"de Francisco","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.165","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61302-7"},{"key":"2026032503500973000_74.Suppl_2.s1.166","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001055","article-title":"Impact of Epstein\u2013Barr virus infection in patients with inflammatory bowel disease","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2026032503500973000_74.Suppl_2.s1.167","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16071"},{"key":"2026032503500973000_74.Suppl_2.s1.168","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12182"},{"key":"2026032503500973000_74.Suppl_2.s1.169","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/ibd\/izac063","article-title":"Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib","volume":"29","author":"Winthrop","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.170","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2026032503500973000_74.Suppl_2.s1.171","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00666-8"},{"key":"2026032503500973000_74.Suppl_2.s1.172","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5217\/ir.2022.00094","article-title":"Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"21","author":"Giri","year":"2023","journal-title":"Intest Res"},{"key":"2026032503500973000_74.Suppl_2.s1.173","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MEG.0000000000002076","article-title":"Review article: safety of new biologic agents for inflammatory bowel disease in the liver","volume":"33","author":"Magr\u00ec","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.174","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/QAD.0000000000000121","article-title":"Azathioprine can be safely used in HIV-infected individuals","volume":"28","author":"Chamberlain","year":"2014","journal-title":"AIDS"},{"key":"2026032503500973000_74.Suppl_2.s1.175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.cgh.2020.12.023","article-title":"Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study","volume":"20","author":"Guillo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.176","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000338"},{"key":"2026032503500973000_74.Suppl_2.s1.177","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2013.08.002"},{"key":"2026032503500973000_74.Suppl_2.s1.178","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1403718"},{"key":"2026032503500973000_74.Suppl_2.s1.179","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.5613"},{"key":"2026032503500973000_74.Suppl_2.s1.180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41395-018-0360-9","article-title":"Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study","volume":"114","author":"Scharl","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.181","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.05.004"},{"key":"2026032503500973000_74.Suppl_2.s1.182","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15665"},{"key":"2026032503500973000_74.Suppl_2.s1.183","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.184","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2026032503500973000_74.Suppl_2.s1.185","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15514"},{"key":"2026032503500973000_74.Suppl_2.s1.186","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223715"},{"key":"2026032503500973000_74.Suppl_2.s1.187","unstructured":"European Medicines Agency . EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2022."},{"key":"2026032503500973000_74.Suppl_2.s1.188","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy243"},{"key":"2026032503500973000_74.Suppl_2.s1.189","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.224154"},{"key":"2026032503500973000_74.Suppl_2.s1.190","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.12.013"},{"key":"2026032503500973000_74.Suppl_2.s1.191","unstructured":"Health. Do . Influenza: The Green Book, Chapter. 1920."},{"key":"2026032503500973000_74.Suppl_2.s1.192","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MIB.0000000000000615","article-title":"Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial","volume":"22","author":"deBruyn","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.193","unstructured":"Health Do . Chapter 18. In: Hepatitis B: The Green Book. 2017."},{"key":"2026032503500973000_74.Suppl_2.s1.194","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/MEG.0000000000000370","article-title":"Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases","volume":"27","author":"Belle","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.195","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13001"},{"key":"2026032503500973000_74.Suppl_2.s1.196","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-1980-8"},{"key":"2026032503500973000_74.Suppl_2.s1.197","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05110.x"},{"key":"2026032503500973000_74.Suppl_2.s1.198","unstructured":"Do. Pneumococcal: The Green Book, 2520."},{"key":"2026032503500973000_74.Suppl_2.s1.199","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S2468-1253(21)00024-8","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement","volume":"6","author":"Alexander","year":"2021","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"2026032503500973000_74.Suppl_2.s1.200","unstructured":"Do. Shingles: The Green Book, Chapter, n.d.:252024."},{"key":"2026032503500973000_74.Suppl_2.s1.201","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327570"},{"key":"2026032503500973000_74.Suppl_2.s1.202","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102249","article-title":"Neutralising antibody responses against SARS-CoV-2 Omicron BA.4\/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study","volume":"64","author":"Liu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026032503500973000_74.Suppl_2.s1.203","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"Din","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.204","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab052"},{"key":"2026032503500973000_74.Suppl_2.s1.205","unstructured":"Joint Committee on Vaccination and Immunisation . JCVI statement on the shingles (herpes Zoster) vaccination programme. 2024."},{"key":"2026032503500973000_74.Suppl_2.s1.206","unstructured":"Department of Health . n.d. Contraindications and special considerations: the green book, Chapter 62013."},{"key":"2026032503500973000_74.Suppl_2.s1.207","first-page":"540","article-title":"Vaccinating patients with inflammatory bowel disease","volume":"12","author":"Reich","year":"2016","journal-title":"Gastroenterol Hepatol (Bartlesville)"},{"key":"2026032503500973000_74.Suppl_2.s1.208","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.3748\/wjg.v21.i11.3184","article-title":"Updates in vaccination: Recommendations for adult inflammatory bowel disease patients","volume":"21","author":"Chaudrey","year":"2015","journal-title":"WJG"},{"key":"2026032503500973000_74.Suppl_2.s1.209","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","article-title":"Vaccinations in patients with immune-mediated inflammatory diseases","volume":"49","author":"Rahier","year":"2010","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026032503500973000_74.Suppl_2.s1.210","unstructured":"Do. Varicella: The Green Book, Chapter 34, 2015."},{"key":"2026032503500973000_74.Suppl_2.s1.211","unstructured":"Available: https:\/\/bnf.nice.org.uk\/?_zk_sc_t=859ebb07c5a13f3f7c8d64d78866b89360ef7b9ff7b07ea6d0167d5c982ed2d59dfaffa503393f229ab85b6f8a2a33bd25193984b91b9bcb51976e8aea858fa90f51c16b5f6cc42c1c177cbe9ac54d646bb7c6e79537b479c456d084117fa1338521ae0956c0b428205ce23c4376845a8d20f6c8fe47d6ba29cafb2e1ef12d585da7e4a2df144795f73887a83ebc6f69b3c597614f8f206fbcdd5c43dcd0c4825c7dc093882abb1cc6e2e3850cc08ae9d0a0eb25c2f1d671bd0fd124a588b44f2ee9e1a1a5b150c3f0dcfbfc48a6101d95aa820d20e01b6f23314975c8dcb238"},{"key":"2026032503500973000_74.Suppl_2.s1.212","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152"},{"key":"2026032503500973000_74.Suppl_2.s1.213","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231188549","article-title":"Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis","volume":"16","author":"Barberio","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.214","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ajg.2015.114","article-title":"Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, parallel group study","volume":"110","author":"Van Assche","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.215","article-title":"Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.216","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.217","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.11481.x"},{"key":"2026032503500973000_74.Suppl_2.s1.218","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0144-2"},{"key":"2026032503500973000_74.Suppl_2.s1.219","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317021"},{"key":"2026032503500973000_74.Suppl_2.s1.220","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/apt.18102","article-title":"Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study","volume":"60","author":"Seo","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.221","doi-asserted-by":"crossref","unstructured":"Chande N , Wang Y , MacDonald JK , et al . n.d. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014. doi:10.1002\/14651858.CD006618.pub3","DOI":"10.1002\/14651858.CD006618.pub3"},{"key":"2026032503500973000_74.Suppl_2.s1.222","doi-asserted-by":"crossref","unstructured":"Wang Y , MacDonald JK , Vandermeer B , et al . n.d. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2015. doi:10.1002\/14651858.CD007560.pub3","DOI":"10.1002\/14651858.CD007560.pub3"},{"key":"2026032503500973000_74.Suppl_2.s1.223","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134382","article-title":"The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD","volume":"12","author":"Demase","year":"2023","journal-title":"J Clin Med"},{"key":"2026032503500973000_74.Suppl_2.s1.224","doi-asserted-by":"crossref","unstructured":"Timmer A , McDonald JWD , Macdonald JK . Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007;CD000478. doi:10.1002\/14651858.CD000478.pub2","DOI":"10.1002\/14651858.CD000478.pub2"},{"key":"2026032503500973000_74.Suppl_2.s1.225","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04023.x"},{"key":"2026032503500973000_74.Suppl_2.s1.226","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16050"},{"key":"2026032503500973000_74.Suppl_2.s1.227","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.05.015"},{"key":"2026032503500973000_74.Suppl_2.s1.228","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws375"},{"key":"2026032503500973000_74.Suppl_2.s1.229","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.050"},{"key":"2026032503500973000_74.Suppl_2.s1.230","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000457"},{"key":"2026032503500973000_74.Suppl_2.s1.231","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jgh.14533","article-title":"Risk of skin cancers in thiopurines\u2010treated and thiopurines\u2010untreated patients with inflammatory bowel disease: A systematic review and meta\u2010analysis","volume":"34","author":"Huang","year":"2019","journal-title":"J of Gastro and Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.232","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6844.20"},{"key":"2026032503500973000_74.Suppl_2.s1.233","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/ecco-jcc\/jjz051","article-title":"European Crohn\u2019s and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease","volume":"13","author":"Torres","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.234","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/apt.14106","article-title":"Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial","volume":"46","author":"Roblin","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.235","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"2026032503500973000_74.Suppl_2.s1.236","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.01.004"},{"key":"2026032503500973000_74.Suppl_2.s1.237","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2026032503500973000_74.Suppl_2.s1.238","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"2026032503500973000_74.Suppl_2.s1.239","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.06.010"},{"key":"2026032503500973000_74.Suppl_2.s1.240","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00535-017-1326-1","article-title":"Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)","volume":"52","author":"Hibi","year":"2017","journal-title":"J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.241","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0922-y"},{"key":"2026032503500973000_74.Suppl_2.s1.242","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"2026032503500973000_74.Suppl_2.s1.243","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.02.033"},{"key":"2026032503500973000_74.Suppl_2.s1.244","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"2026032503500973000_74.Suppl_2.s1.245","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00062-5"},{"key":"2026032503500973000_74.Suppl_2.s1.246","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"2026032503500973000_74.Suppl_2.s1.247","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"The Lancet"},{"key":"2026032503500973000_74.Suppl_2.s1.248","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"2026032503500973000_74.Suppl_2.s1.249","unstructured":"Agency EM . Ema CONFIRMS measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 2023."},{"key":"2026032503500973000_74.Suppl_2.s1.250","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5"},{"key":"2026032503500973000_74.Suppl_2.s1.251","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2207940"},{"key":"2026032503500973000_74.Suppl_2.s1.252","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000995752.19097.c8","article-title":"S4\u2003Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study","volume":"118","author":"Louis","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.253","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"2026032503500973000_74.Suppl_2.s1.254","unstructured":"Motoya S , Watanabe K , Ogata H . A phase 3 study of Vedolizumab in Japanese patients with ulcerative colitis: effects on time to disease worsening and treatment failure. United European Gastroenterol J 2018;6."},{"key":"2026032503500973000_74.Suppl_2.s1.255","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"2026032503500973000_74.Suppl_2.s1.256","article-title":"Antibiotics for the induction and maintenance of remission in ulcerative colitis","volume":"5","author":"Gordon","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.257","article-title":"Fecal transplantation for treatment of inflammatory bowel disease","volume":"11","author":"Imdad","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.258","article-title":"Probiotics for induction of remission in ulcerative colitis","volume":"3","author":"Kaur","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.259","article-title":"Probiotics for maintenance of remission in ulcerative colitis","volume":"3","author":"Iheozor-Ejiofor","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.260","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1365-2036.2011.04619.x","article-title":"Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis","volume":"33","author":"Harris","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.261","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/apt.17666","article-title":"Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis","volume":"58","author":"Aruljothy","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.262","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02185.x"},{"key":"2026032503500973000_74.Suppl_2.s1.263","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.228_a.x"},{"key":"2026032503500973000_74.Suppl_2.s1.264","first-page":"1079","article-title":"5-Aminosalicylic acid Suppositories in the maintenance of remission in idiopathic Proctitis or Proctosigmoiditis: a double-blind placebo-controlled clinical trial","volume":"85","author":"D\u2019Arienzo","year":"1990","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.265","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.2.195"},{"key":"2026032503500973000_74.Suppl_2.s1.266","doi-asserted-by":"publisher","DOI":"10.3109\/00365529509093256"},{"key":"2026032503500973000_74.Suppl_2.s1.267","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198808000-00012"},{"key":"2026032503500973000_74.Suppl_2.s1.268","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21258"},{"key":"2026032503500973000_74.Suppl_2.s1.269","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00259.x"},{"key":"2026032503500973000_74.Suppl_2.s1.270","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000171277.70404.40"},{"key":"2026032503500973000_74.Suppl_2.s1.271","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/00365529008997590","article-title":"Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial","volume":"25","author":"Campieri","year":"1990","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.272","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2036.1988.tb00668.x","article-title":"Double\u2010blind comparison of 5\u2010aminosalicylic acid and acetyl\u20105\u2010aminosalicylic acid suppositories in patients with idiopathic proctitis","volume":"2","author":"Hogezand","year":"1988","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.273","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01940.x"},{"key":"2026032503500973000_74.Suppl_2.s1.274","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.04.027"},{"key":"2026032503500973000_74.Suppl_2.s1.275","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/ecco-jcc\/jjac081","article-title":"Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial","volume":"16","author":"Kruis","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.276","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02743.x"},{"key":"2026032503500973000_74.Suppl_2.s1.277","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00042737-199606000-00010","article-title":"Beclomethasone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3mg\/2g) as retention enemas in active ulcerative proctitis","volume":"8","author":"Mulder","year":"1996","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"2026032503500973000_74.Suppl_2.s1.278","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-2000-14869","article-title":"Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study","volume":"38","author":"Rufle","year":"2000","journal-title":"Z Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.279","first-page":"1867","article-title":"A double-blind comparison of oral versus Rectal Mesalamine versus combination therapy in the treatment of distal ulcerative colitis","volume":"92","author":"Safdi","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.280","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.060"},{"key":"2026032503500973000_74.Suppl_2.s1.281","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1177\/2050640620941345","article-title":"Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort","volume":"8","author":"Dubois","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2026032503500973000_74.Suppl_2.s1.282","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.02.027"},{"key":"2026032503500973000_74.Suppl_2.s1.283","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/jgh.16111","article-title":"Systematic review of therapies for refractory ulcerative proctitis","volume":"38","author":"Raja","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.284","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10620-024-08276-1","article-title":"Effectiveness of Tofacitinib in Ulcerative Proctitis Compared to Left Sided Colitis and Pancolitis","volume":"69","author":"Singh","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026032503500973000_74.Suppl_2.s1.285","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13491"},{"key":"2026032503500973000_74.Suppl_2.s1.286","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4947.1041"},{"key":"2026032503500973000_74.Suppl_2.s1.287","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15592"},{"key":"2026032503500973000_74.Suppl_2.s1.288","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.289","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.13614","article-title":"Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data","volume":"43","author":"Lynch","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.290","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12073"},{"key":"2026032503500973000_74.Suppl_2.s1.291","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.crohns.2011.09.005","article-title":"Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis","volume":"6","author":"Navaneethan","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.292","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02606-13"},{"key":"2026032503500973000_74.Suppl_2.s1.293","doi-asserted-by":"publisher","DOI":"10.1080\/003655201750305503"},{"key":"2026032503500973000_74.Suppl_2.s1.294","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03418.x"},{"key":"2026032503500973000_74.Suppl_2.s1.295","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.09.033"},{"key":"2026032503500973000_74.Suppl_2.s1.296","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1111\/jgh.15535","article-title":"A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease","volume":"36","author":"Schauer","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.297","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199002000-00011"},{"key":"2026032503500973000_74.Suppl_2.s1.298","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.6874"},{"key":"2026032503500973000_74.Suppl_2.s1.299","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2036.2010.04392.x","article-title":"Review article: the optimal medical management of acute severe ulcerative colitis","volume":"32","author":"Hart","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.300","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01435.x"},{"key":"2026032503500973000_74.Suppl_2.s1.301","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0105","article-title":"DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial","volume":"18","author":"Amiot","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.302","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy222.280","article-title":"P156 Long-term outcomes of steroid-responsive and non-responsive patients with acute severe ulcerative colitis","volume":"13","author":"Bernardo","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.303","first-page":"i1082","article-title":"P550 Short and long-term outcomes after acute severe ulcerative colitis in adults: A 12 year Canadian experience in the post biologic era","volume":"18","author":"Vuyyuru","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.304","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15751"},{"key":"2026032503500973000_74.Suppl_2.s1.305","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61084-8"},{"key":"2026032503500973000_74.Suppl_2.s1.306","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313060"},{"key":"2026032503500973000_74.Suppl_2.s1.307","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30003-6"},{"key":"2026032503500973000_74.Suppl_2.s1.308","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.7"},{"key":"2026032503500973000_74.Suppl_2.s1.309","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1038\/ajg.2017.180","article-title":"Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study","volume":"112","author":"Ord\u00e1s","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.310","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2012.08.002"},{"key":"2026032503500973000_74.Suppl_2.s1.311","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/1751-2980.12278","article-title":"Surgical and medical treatment in patients with acute severe ulcerative colitis","volume":"16","author":"Fornaro","year":"2015","journal-title":"J Dig Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.312","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.183095"},{"key":"2026032503500973000_74.Suppl_2.s1.313","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.035"},{"key":"2026032503500973000_74.Suppl_2.s1.314","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.13913","article-title":"Review article: dose optimisation of infliximab for acute severe ulcerative colitis","volume":"45","author":"Hindryckx","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.315","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308099"},{"key":"2026032503500973000_74.Suppl_2.s1.316","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.10.029"},{"key":"2026032503500973000_74.Suppl_2.s1.317","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.07.041"},{"key":"2026032503500973000_74.Suppl_2.s1.318","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10620-018-5407-7","article-title":"Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis","volume":"64","author":"Sebastian","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2026032503500973000_74.Suppl_2.s1.319","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.1002","article-title":"P872 PREDICT UC: Optimising Infliximab Induction therapy for Acute Severe Ulcerative Colitis \u2013 A Randomised Controlled Trial","volume":"18","author":"Choy","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.320","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/MPG.0000000000003616","article-title":"Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis","volume":"75","author":"Constant","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026032503500973000_74.Suppl_2.s1.321","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","article-title":"Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study","volume":"19","author":"Berinstein","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.322","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0086","article-title":"Dop46 tofacitinib for hospitalized acute severe ulcerative colitis \u2013 the triumph study","volume":"18","author":"Narula","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.323","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/ibd\/izad180","article-title":"Upadacitinib for Acute Severe Ulcerative Colitis","volume":"29","author":"Zinger","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.324","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.325","article-title":"Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease","volume":"10","author":"Law","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.326","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01942.x"},{"key":"2026032503500973000_74.Suppl_2.s1.327","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00883-7"},{"key":"2026032503500973000_74.Suppl_2.s1.328","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/apt.12947","article-title":"Review article: optimal preparation for surgery in Crohn\u2019s disease","volume":"40","author":"Spinelli","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.329","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000000099"},{"key":"2026032503500973000_74.Suppl_2.s1.330","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1097\/MIB.0000000000000919","article-title":"Preoperative Anti\u2013tumor Necrosis Factor Therapy in Patients with Ulcerative Colitis Is Not Associated with an Increased Risk of Infectious and Noninfectious Complications After Ileal Pouch\u2013anal Anastomosis","volume":"22","author":"Zittan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.331","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000381033","article-title":"Safety of Proctocolectomy for Ulcerative Colitis Under Elective and Non-Elective Circumstances: Preoperative Corticosteroid Treatment Worsens Outcome","volume":"32","author":"Balachandran","year":"2015","journal-title":"Dig Surg"},{"key":"2026032503500973000_74.Suppl_2.s1.332","first-page":"32","volume-title":"A prospective, randomized, noninferiority trial of steroid dosing after major colorectal surgery","volume":"259","author":"Zaghiyan","year":"2014"},{"key":"2026032503500973000_74.Suppl_2.s1.333","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/DCR.0b013e3182a180b7","article-title":"Impact of Stress Dose Steroids on the Outcomes of Restorative Proctocolectomy in Patients With Ulcerative Colitis","volume":"56","author":"Aytac","year":"2013","journal-title":"Dis Colon Rectum"},{"key":"2026032503500973000_74.Suppl_2.s1.334","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/gastro\/gow046","article-title":"Perioperative use of immunosuppressive medications in patients with Crohn\u2019s disease in the new \u201cbiological era\u201d","volume":"5","author":"Lightner","year":"2017","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2026032503500973000_74.Suppl_2.s1.335","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.143.12.1222"},{"key":"2026032503500973000_74.Suppl_2.s1.336","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12313"},{"key":"2026032503500973000_74.Suppl_2.s1.337","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12060"},{"key":"2026032503500973000_74.Suppl_2.s1.338","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.03.057"},{"key":"2026032503500973000_74.Suppl_2.s1.339","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/ibd\/izx076","article-title":"Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study","volume":"24","author":"Lightner","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.340","doi-asserted-by":"publisher","DOI":"10.1093\/eccojcc\/jjy022"},{"key":"2026032503500973000_74.Suppl_2.s1.341","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-0750-5"},{"key":"2026032503500973000_74.Suppl_2.s1.342","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.386"},{"key":"2026032503500973000_74.Suppl_2.s1.343","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(03)00434-4"},{"key":"2026032503500973000_74.Suppl_2.s1.344","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e31819a5cc1"},{"key":"2026032503500973000_74.Suppl_2.s1.345","doi-asserted-by":"crossref","first-page":"O153","DOI":"10.1111\/codi.13658","article-title":"Subtotal colectomy for ulcerative colitis: lessons learned from a tertiary centre","volume":"19","author":"Buchs","year":"2017","journal-title":"Colorectal Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.346","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.08.012"},{"key":"2026032503500973000_74.Suppl_2.s1.347","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000000418"},{"key":"2026032503500973000_74.Suppl_2.s1.348","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00384-013-1814-6","article-title":"Quality of life after proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis","volume":"29","author":"Koerdt","year":"2014","journal-title":"Int J Colorectal Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.349","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31827d99a2"},{"key":"2026032503500973000_74.Suppl_2.s1.350","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1318.2010.02538.x"},{"key":"2026032503500973000_74.Suppl_2.s1.351","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e318217eea7"},{"key":"2026032503500973000_74.Suppl_2.s1.352","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.crohns.2013.12.007","article-title":"Outcomes after Ileal pouch Anal anastomosis in patients with primary Sclerosing cholangitis","volume":"8","author":"Pavlides","year":"2014","journal-title":"Journal of Crohn's and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.353","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.02.006"},{"key":"2026032503500973000_74.Suppl_2.s1.354","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001061"},{"key":"2026032503500973000_74.Suppl_2.s1.355","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.035"},{"key":"2026032503500973000_74.Suppl_2.s1.356","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.10.015"},{"key":"2026032503500973000_74.Suppl_2.s1.357","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200111000-00004"},{"key":"2026032503500973000_74.Suppl_2.s1.358","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01139.x"},{"key":"2026032503500973000_74.Suppl_2.s1.359","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1569718"},{"key":"2026032503500973000_74.Suppl_2.s1.360","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00034-7"},{"key":"2026032503500973000_74.Suppl_2.s1.361","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.1149","article-title":"P0975 Cost-effectiveness analysis of anti-TNF treatment from diagnosis for patients with moderate and severe Crohn\u2019s disease: an analysis using data from the PROFILE trial","volume":"19","author":"Noor","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.362","article-title":"Traditional corticosteroids for induction of remission in Crohn\u2019s disease","volume":"2008","author":"Benchimol","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.363","doi-asserted-by":"crossref","unstructured":"Steinhart AH , Ewe K , Griffiths AM , et al . Corticosteroids for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2003;CD000301. doi:10.1002\/14651858.CD000301","DOI":"10.1002\/14651858.CD000301"},{"key":"2026032503500973000_74.Suppl_2.s1.364","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwy018"},{"key":"2026032503500973000_74.Suppl_2.s1.365","doi-asserted-by":"crossref","unstructured":"Lim W-C , Hanauer S . Aminosalicylates for induction of remission or response in Crohn\u2019s disease. Cochrane Database Syst Rev 2010;CD008870. doi:10.1002\/14651858.CD008870","DOI":"10.1002\/14651858.CD008870"},{"key":"2026032503500973000_74.Suppl_2.s1.366","doi-asserted-by":"crossref","unstructured":"Akobeng AK , Zhang D , Gordon M , et al . n.d. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2016. doi:10.1002\/14651858.CD003715.pub3","DOI":"10.1002\/14651858.CD003715.pub3"},{"key":"2026032503500973000_74.Suppl_2.s1.367","doi-asserted-by":"crossref","unstructured":"McDonald JW , Wang Y , Tsoulis DJ , et al . n.d. Methotrexate for induction of remission in refractory Crohn\u2019s disease. Cochrane Database Syst Rev 2015. doi:10.1002\/14651858.CD003459.pub4","DOI":"10.1002\/14651858.CD003459.pub4"},{"key":"2026032503500973000_74.Suppl_2.s1.368","doi-asserted-by":"crossref","unstructured":"Patel V , Macdonald JK , McDonald JW , et al . Methotrexate for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2009;CD006884. doi:10.1002\/14651858.CD006884.pub2","DOI":"10.1002\/14651858.CD006884.pub2"},{"key":"2026032503500973000_74.Suppl_2.s1.369","doi-asserted-by":"crossref","unstructured":"Chande N , Tsoulis DJ , MacDonald JK . Azathioprine or 6\u2010Mercaptopurine for induction of remission in Crohn\u2019S disease. Cochrane Database Syst Rev 2013.","DOI":"10.1002\/14651858.CD000545.pub4"},{"key":"2026032503500973000_74.Suppl_2.s1.370","doi-asserted-by":"crossref","unstructured":"Chande N , Patton PH , Tsoulis DJ . Azathioprine or 6\u2010Mercaptopurine for maintenance of remission in Crohn\u2019S disease. Cochrane Database Syst Rev 2015;10.","DOI":"10.1002\/14651858.CD000545.pub5"},{"key":"2026032503500973000_74.Suppl_2.s1.371","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2020-101405"},{"key":"2026032503500973000_74.Suppl_2.s1.372","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101332","article-title":"Low-dose azathioprine and allopurinol versus azathioprine monotherapy in patients with ulcerative colitis (AAUC): An investigator-initiated, open, multicenter, parallel-arm, randomised controlled trial","volume":"45","author":"Kiszka-Kanowitz","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026032503500973000_74.Suppl_2.s1.373","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/MIB.0000000000000827","article-title":"Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study","volume":"22","author":"Pavlidis","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.374","article-title":"Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn\u2019s disease","volume":"5","author":"Boyapati","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.375","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw152"},{"key":"2026032503500973000_74.Suppl_2.s1.376","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820938960","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn\u2019s disease: results from a randomized trial","volume":"13","author":"Chen","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.377","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00159"},{"key":"2026032503500973000_74.Suppl_2.s1.378","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.379","doi-asserted-by":"crossref","unstructured":"Gordon M , Sinopoulou V , Akobeng AK , et al . Infliximab for medical induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2023;11. doi:10.1002\/14651858.CD012623.pub2","DOI":"10.1002\/14651858.CD012623.pub2"},{"key":"2026032503500973000_74.Suppl_2.s1.380","article-title":"Infliximab for maintenance of medically-induced remission in Crohn\u2019s disease","volume":"2","author":"Gordon","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.381","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904492"},{"key":"2026032503500973000_74.Suppl_2.s1.382","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60304-9"},{"key":"2026032503500973000_74.Suppl_2.s1.383","first-page":"229","article-title":"Efficacy of Infliximab combined with azathioprine for moderate to severe Crohn\u2019S disease","volume":"18","author":"Duan","year":"2013","journal-title":"Chinese Journal of Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.384","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.02.014"},{"key":"2026032503500973000_74.Suppl_2.s1.385","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20014"},{"key":"2026032503500973000_74.Suppl_2.s1.386","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of Biosimilar ct-P13 compared with Originator Infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"key":"2026032503500973000_74.Suppl_2.s1.387","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200061","article-title":"Discontinuation of Infliximab Therapy in Patients with Crohn\u2019s Disease","volume":"1","author":"Buhl","year":"2022","journal-title":"NEJM Evid"},{"key":"2026032503500973000_74.Suppl_2.s1.388","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)70140-5"},{"key":"2026032503500973000_74.Suppl_2.s1.389","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200316432"},{"key":"2026032503500973000_74.Suppl_2.s1.390","doi-asserted-by":"publisher","DOI":"10.1038\/ncpgasthep1000"},{"key":"2026032503500973000_74.Suppl_2.s1.391","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1093\/ibd\/izy173","article-title":"6-Thioguanine Nucleotide Levels Are Associated With Mucosal Healing in Patients With Crohn\u2019s Disease","volume":"24","author":"Mao","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.392","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000439068.71126.00"},{"key":"2026032503500973000_74.Suppl_2.s1.393","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.01.046"},{"key":"2026032503500973000_74.Suppl_2.s1.394","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200406000-00016"},{"key":"2026032503500973000_74.Suppl_2.s1.395","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03782.x"},{"key":"2026032503500973000_74.Suppl_2.s1.396","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315579063"},{"key":"2026032503500973000_74.Suppl_2.s1.397","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3060"},{"key":"2026032503500973000_74.Suppl_2.s1.398","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/apt.16137","article-title":"NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India","volume":"52","author":"Banerjee","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.399","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/17512433.2023.2232300","article-title":"Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review","volume":"16","author":"Desai","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026032503500973000_74.Suppl_2.s1.400","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2023-001149","article-title":"Association between 6-thioguanine nucleotide levels and preventing production of antibodies to infliximab in patients with inflammatory bowel disease","volume":"10","author":"Phillips","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.401","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1016\/j.cgh.2022.10.016","article-title":"Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab","volume":"21","author":"Yarur","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.402","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/ecco-jcc\/jjx149","article-title":"A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease","volume":"12","author":"Mogensen","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.403","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.12.026"},{"key":"2026032503500973000_74.Suppl_2.s1.404","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000518755","article-title":"Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?","volume":"7","author":"Shmais","year":"2022","journal-title":"Inflamm Intest Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.405","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/j.gastro.2022.06.052","article-title":"Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis","volume":"163","author":"Nguyen","year":"2022","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.406","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/apt.17313","article-title":"Meta-analysis: The efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease","volume":"57","author":"Sethi","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.407","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.031"},{"key":"2026032503500973000_74.Suppl_2.s1.408","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.4172"},{"key":"2026032503500973000_74.Suppl_2.s1.409","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn\u2019s Disease","volume":"154","author":"D\u2019Haens","year":"2018","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.410","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.411","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.06.003"},{"key":"2026032503500973000_74.Suppl_2.s1.412","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.413","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1053\/j.gastro.2022.02.014","article-title":"Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives","volume":"162","author":"Irving","year":"2022","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.414","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0073-0"},{"key":"2026032503500973000_74.Suppl_2.s1.415","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.416","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/00365521.2023.2285229","article-title":"Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses","volume":"59","author":"Harno-Tasihin","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.417","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","article-title":"Higher Serum Infliximab Concentrations Following Subcutaneous Dosing are Associated with Deep Remission in Patients with Inflammatory Bowel Disease","volume":"18","author":"Roblin","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.418","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.cgh.2020.03.002","article-title":"Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases","volume":"19","author":"Papamichael","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.419","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.12"},{"key":"2026032503500973000_74.Suppl_2.s1.420","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2012.06.002"},{"key":"2026032503500973000_74.Suppl_2.s1.421","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201310001-01817","article-title":"Homogenous Mobility Shift Assay (HMSA) Overcomes the Limitations of ELISA and ECLIA Assays for Monitoring Infliximab (IFX), Adalimumab (ADA), and Associated Anti-drug Antibodies in Serum","volume":"108","author":"Egea-Pujol","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.422","first-page":"1","article-title":"The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"35","author":"Fousekis","year":"2022","journal-title":"Ann Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.423","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1007\/s10620-024-08515-5","article-title":"Reactive Immunomodulator Addition to Infliximab Monotherapy Restores Clinical Response in Inflammatory Bowel Disease: A Meta-Analysis","volume":"69","author":"Lowell","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2026032503500973000_74.Suppl_2.s1.424","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/00365521.2023.2278424","article-title":"Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies","volume":"59","author":"Anjie","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.425","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13243"},{"key":"2026032503500973000_74.Suppl_2.s1.426","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.427","first-page":"412","article-title":"Long-term efficacy of Vedolizumab for Crohn\u2019S disease","volume":"11","author":"Vermeire","year":"2017","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.428","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"2026032503500973000_74.Suppl_2.s1.429","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.03.025"},{"key":"2026032503500973000_74.Suppl_2.s1.430","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602773"},{"key":"2026032503500973000_74.Suppl_2.s1.431","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn\u2019s Disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.432","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00474-X"},{"key":"2026032503500973000_74.Suppl_2.s1.433","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/apt.17751","article-title":"Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn\u2019s disease: Results from the long-term extension period of STARDUST","volume":"59","author":"Peyrin-Biroulet","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.434","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/apt.16544","article-title":"Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study","volume":"54","author":"Fumery","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.435","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jcag\/gwac017","article-title":"Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn\u2019s Disease With a Loss of Response","volume":"5","author":"Heron","year":"2022","journal-title":"J Can Assoc Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.436","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","article-title":"Effectiveness of Reinduction and\/or Dose Escalation of Ustekinumab in Crohn\u2019s Disease: A Systematic Review and Meta-analysis","volume":"20","author":"Meserve","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.437","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00385-5"},{"key":"2026032503500973000_74.Suppl_2.s1.438","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(21)01844-8"},{"key":"2026032503500973000_74.Suppl_2.s1.439","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.004"},{"key":"2026032503500973000_74.Suppl_2.s1.440","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00535-019-01582-w","article-title":"Withdrawal of thiopurines in Crohn\u2019s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)","volume":"54","author":"Hisamatsu","year":"2019","journal-title":"J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.441","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16182"},{"key":"2026032503500973000_74.Suppl_2.s1.442","unstructured":"Choi G , Park D , Park J . Withdrawal of azathioprine in Luminal Crohn\u2019S disease treated with Infliximab maintenance therapy: a retrospective case-control study. J Gastroenterol Hepatol 2010."},{"key":"2026032503500973000_74.Suppl_2.s1.443","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1093\/ecco-jcc\/jjx180.806","article-title":"P679 Risk factors for disease relapse after stepping down from combination to anti-TNF monotherapy in children with IBD","volume":"12","author":"Yerushalmy-Feler","year":"2018","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.444","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAC187"},{"key":"2026032503500973000_74.Suppl_2.s1.445","unstructured":"MacDonald JK , Nguyen TM , Khanna R , et al . n.d. Anti-IL-12\/23p40 antibodies for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev."},{"key":"2026032503500973000_74.Suppl_2.s1.446","article-title":"Anti-IL-12\/23p40 antibodies for maintenance of remission in Crohn\u2019s disease","volume":"12","author":"Davies","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.447","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314585"},{"key":"2026032503500973000_74.Suppl_2.s1.448","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212728"},{"key":"2026032503500973000_74.Suppl_2.s1.449","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn\u2019s Disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.450","article-title":"Vedolizumab for induction and maintenance of remission in Crohn\u2019s disease","volume":"7","author":"Hui","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.451","article-title":"Antibiotics for induction and maintenance of remission in Crohn\u2019s disease","volume":"2","author":"Townsend","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.452","doi-asserted-by":"crossref","DOI":"10.1186\/1471-230X-4-5","article-title":"Lactobacillus GG in inducing and maintaining remission of Crohn\u2019s disease","volume":"4","author":"Schultz","year":"2004","journal-title":"BMC Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.453","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04417.x"},{"key":"2026032503500973000_74.Suppl_2.s1.454","article-title":"Probiotics for induction of remission in Crohn\u2019s disease","volume":"7","author":"Limketkai","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.455","doi-asserted-by":"crossref","unstructured":"Rolfe VE , Fortun PJ , Hawkey CJ , et al . Probiotics for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev 2006;CD004826. doi:10.1002\/14651858.CD004826.pub2","DOI":"10.1002\/14651858.CD004826.pub2"},{"key":"2026032503500973000_74.Suppl_2.s1.456","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03431.x"},{"key":"2026032503500973000_74.Suppl_2.s1.457","article-title":"Enteral nutritional therapy for induction of remission in Crohn\u2019s disease","volume":"4","author":"Narula","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.458","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The Medical Management of Paediatric Crohn\u2019s Disease: an ECCO-ESPGHAN Guideline Update","volume":"15","author":"van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.459","doi-asserted-by":"publisher","DOI":"10.1080\/08035250310008050"},{"key":"2026032503500973000_74.Suppl_2.s1.460","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01527.x"},{"key":"2026032503500973000_74.Suppl_2.s1.461","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/ibd\/izac039","article-title":"Comparing Effectiveness of a Generic Oral Nutritional Supplement With Specialized Formula in the Treatment of Active Pediatric Crohn\u2019s Disease","volume":"28","author":"Dawson","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.462","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13934"},{"key":"2026032503500973000_74.Suppl_2.s1.463","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00365521.2016.1221994","article-title":"Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn\u2019s disease","volume":"52","author":"Beaupel","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.464","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/codi.14922","article-title":"Does preoperative enteral nutrition reduce the incidence of surgical complications in patients with Crohn\u2019s disease? A case-matched study","volume":"22","author":"Yamamoto","year":"2020","journal-title":"Colorectal Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.465","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clnesp.2021.09.723","article-title":"The role of exclusive enteral nutrition in the pre-operative optimisation of adult patients with Crohn\u2019s disease. A systematic review","volume":"46","author":"Gordon-Dixon","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"2026032503500973000_74.Suppl_2.s1.466","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1002\/jum.16225","article-title":"Comparison of MRI and Endoanal Ultrasound in Assessing Intersphincteric, Transsphincteric, and Suprasphincteric Perianal Fistula","volume":"42","author":"Akhoundi","year":"2023","journal-title":"J Ultrasound Med"},{"key":"2026032503500973000_74.Suppl_2.s1.467","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/ibd\/izy329","article-title":"Update on the Natural Course of Fistulizing Perianal Crohn\u2019s Disease in a Population-Based Cohort","volume":"25","author":"Park","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.468","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28676"},{"key":"2026032503500973000_74.Suppl_2.s1.469","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.022"},{"key":"2026032503500973000_74.Suppl_2.s1.470","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00007-3"},{"key":"2026032503500973000_74.Suppl_2.s1.471","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.04.023"},{"key":"2026032503500973000_74.Suppl_2.s1.472","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306709"},{"key":"2026032503500973000_74.Suppl_2.s1.473","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/17434440.2023.2283166","article-title":"Recent advances in the use of ultrasound in Crohn\u2019s disease","volume":"20","author":"Barchi","year":"2023","journal-title":"Expert Rev Med Devices"},{"key":"2026032503500973000_74.Suppl_2.s1.474","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1895694","article-title":"3D-EAUS and MRI in the Activity of Anal Fistulas in Crohn\u2019s Disease","volume":"2016","author":"Alabiso","year":"2016","journal-title":"Gastroenterol Res Pract"},{"key":"2026032503500973000_74.Suppl_2.s1.475","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.07.027"},{"key":"2026032503500973000_74.Suppl_2.s1.476","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.21.26615"},{"key":"2026032503500973000_74.Suppl_2.s1.477","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01427.x"},{"key":"2026032503500973000_74.Suppl_2.s1.478","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1046\/j.1572-0241.2003.04009.x","article-title":"Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn\u2019s disease","volume":"99","author":"Rasul","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.479","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/apt.14969","article-title":"The role of multimodal treatment in Crohn\u2019s disease patients with perianal fistula: a multicentre retrospective cohort study","volume":"48","author":"Sebastian","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.480","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000315"},{"key":"2026032503500973000_74.Suppl_2.s1.481","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ecco-jcc\/jjaa004","article-title":"Treatment of Perianal Fistulas in Crohn\u2019s Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial","volume":"14","author":"Wasmann","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.482","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2468-1253(22)00088-7","article-title":"Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn\u2019s disease (PISA-II): a patient preference randomised trial","volume":"7","author":"Meima-van Praag","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.483","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.12.042"},{"key":"2026032503500973000_74.Suppl_2.s1.484","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1177\/0003134820956331","article-title":"Modern Management of Perianal Crohn\u2019s Disease: A Review","volume":"87","author":"Williams","year":"2021","journal-title":"Am Surg"},{"key":"2026032503500973000_74.Suppl_2.s1.485","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/ecco-jcc\/jjad212.0018","article-title":"OP18 Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn\u2019s Disease: results from the global ADMIRE-CD II phase 3 study","volume":"18","author":"Serclova","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.486","doi-asserted-by":"publisher","DOI":"10.1007\/s002680010250"},{"key":"2026032503500973000_74.Suppl_2.s1.487","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/ecco-jcc\/jjad159","article-title":"Temporary Faecal Diversion for Refractory Perianal and\/or Distal Colonic Crohn\u2019s Disease in the Biologic Era: An Updated Systematic Review with Meta-analysis","volume":"18","author":"Jew","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.488","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030815"},{"key":"2026032503500973000_74.Suppl_2.s1.489","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/ecco-jcc\/jjad185","article-title":"Pharmacological Therapies for the Management of Fistulizing Crohn\u2019s Disease: A Systematic Review and Meta-Analysis","volume":"18","author":"Vuyyuru","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.490","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20608"},{"key":"2026032503500973000_74.Suppl_2.s1.491","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.106781"},{"key":"2026032503500973000_74.Suppl_2.s1.492","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"2026032503500973000_74.Suppl_2.s1.493","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.159251"},{"key":"2026032503500973000_74.Suppl_2.s1.494","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13970"},{"key":"2026032503500973000_74.Suppl_2.s1.495","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju026"},{"key":"2026032503500973000_74.Suppl_2.s1.496","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of Vedolizumab in Fistulising Crohn\u2019s Disease: Exploratory Analyses of Data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.497","doi-asserted-by":"crossref","first-page":"i620","DOI":"10.1093\/ecco-jcc\/jjac190.0621","article-title":"P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn\u2019s disease","volume":"17","author":"Colombel","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.498","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21551"},{"key":"2026032503500973000_74.Suppl_2.s1.499","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.039"},{"key":"2026032503500973000_74.Suppl_2.s1.500","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-011-1338-x"},{"key":"2026032503500973000_74.Suppl_2.s1.501","doi-asserted-by":"crossref","DOI":"10.1186\/s12893-018-0425-0","article-title":"No effect of anti-TNF-\u03b1 agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study","volume":"18","author":"El-Hussuna","year":"2018","journal-title":"BMC Surg"},{"key":"2026032503500973000_74.Suppl_2.s1.502","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/ibd\/izad174","article-title":"Micronutrient Status and Prediction of Disease Outcome in Adults With Inflammatory Bowel Disease Receiving Biologic Therapy","volume":"30","author":"Brownson","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.503","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otad007","article-title":"High Burden of Obesity and Low Rates of Weight Loss Pharmacotherapy in Inflammatory Bowel Disease: 10-Year Trend","volume":"5","author":"Elangovan","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"2026032503500973000_74.Suppl_2.s1.504","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s11605-014-2672-4","article-title":"Obesity, regardless of comorbidity, influences outcomes after colorectal surgery-time to rethink the pay-for-performance metrics?","volume":"18","author":"Esemuede","year":"2014","journal-title":"J Gastrointest Surg"},{"key":"2026032503500973000_74.Suppl_2.s1.505","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/MPG.0000000000003251","article-title":"Obesity Increases the Risk of Hospital Readmission Following Intestinal Surgery for Children With Crohn Disease","volume":"73","author":"Egberg","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026032503500973000_74.Suppl_2.s1.506","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16460-4","article-title":"The impact of preoperative oral nutrition supplementation on outcomes in patients undergoing gastrointestinal surgery for cancer in low- and middle-income countries: a systematic review and meta-analysis","volume":"12","author":"Knight","year":"2022","journal-title":"Sci Rep"},{"key":"2026032503500973000_74.Suppl_2.s1.507","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/MEG.0000000000001162","article-title":"Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn\u2019s disease patients: a meta-analysis","volume":"30","author":"Brennan","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.508","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.12.027"},{"key":"2026032503500973000_74.Suppl_2.s1.509","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00384-020-03507-z","article-title":"Strictureplasty versus bowel resection for the surgical management of fibrostenotic Crohn\u2019s disease: a systematic review and meta-analysis","volume":"35","author":"Butt","year":"2020","journal-title":"Int J Colorectal Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.510","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312581"},{"key":"2026032503500973000_74.Suppl_2.s1.511","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/apt.13388","article-title":"Systematic review with meta-analysis: endoscopic balloon dilatation for Crohn\u2019s disease strictures","volume":"42","author":"Morar","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.512","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1007\/s00464-016-4902-1","article-title":"Endoscopic balloon dilation in the management of strictures in Crohn\u2019s disease: a systematic review and meta-analysis of non-randomized trials","volume":"30","author":"Navaneethan","year":"2016","journal-title":"Surg Endosc"},{"key":"2026032503500973000_74.Suppl_2.s1.513","doi-asserted-by":"publisher","DOI":"10.1177\/2050640614547805"},{"key":"2026032503500973000_74.Suppl_2.s1.514","doi-asserted-by":"crossref","DOI":"10.1016\/S1873-9946(14)60024-6","article-title":"OP023 Optimising post-operative Crohn\u2019s disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study","volume":"8","author":"Kamm","year":"2014","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.515","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.dld.2020.03.020","article-title":"Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn\u2019s disease","volume":"52","author":"Boube","year":"2020","journal-title":"Dig Liver Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.516","unstructured":"Bowel Ultrasonography in the management of Crohn\u2019S disease . A review with recommendations of an international panel of experts. 2016."},{"key":"2026032503500973000_74.Suppl_2.s1.517","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/ibd\/izy392","article-title":"Ultrasound vs Endoscopy, Surgery, or Pathology for the Diagnosis of Small Bowel Crohn\u2019s Disease and its Complications","volume":"25","author":"Bollegala","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.518","article-title":"Interventions for maintenance of surgically induced remission in Crohn\u2019s disease: a network meta-analysis","volume":"9","author":"Iheozor-Ejiofor","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.519","doi-asserted-by":"publisher","DOI":"10.1007\/s10151-014-1177-1"},{"key":"2026032503500973000_74.Suppl_2.s1.520","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.04.020"},{"key":"2026032503500973000_74.Suppl_2.s1.521","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.051"},{"key":"2026032503500973000_74.Suppl_2.s1.522","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21928"},{"key":"2026032503500973000_74.Suppl_2.s1.523","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.072"},{"key":"2026032503500973000_74.Suppl_2.s1.524","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac100"},{"key":"2026032503500973000_74.Suppl_2.s1.525","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.dld.2022.07.013","article-title":"Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn\u2019s disease: Results from the ENEIDA registry","volume":"55","author":"Ma\u00f1osa","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.526","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac190.0014","article-title":"OP14 Prevention of postoperative recurrence of Crohn\u2019s disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO","volume":"17","author":"D\u2019Haens","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.527","article-title":"Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn\u2019s disease","volume":"8","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.528","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn\u2019s disease","volume":"6","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.529","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15859"},{"key":"2026032503500973000_74.Suppl_2.s1.530","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001697","article-title":"Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF","volume":"8","author":"Cachen","year":"2022","journal-title":"RMD Open"},{"key":"2026032503500973000_74.Suppl_2.s1.531","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.532","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.17831","article-title":"Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study)","volume":"59","author":"Vasudevan","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.533","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.12659\/MSM.913152","article-title":"Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study","volume":"25","author":"Wang","year":"2019","journal-title":"Med Sci Monit"},{"key":"2026032503500973000_74.Suppl_2.s1.534","first-page":"680","article-title":"The risk of venous thromboembolic events in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"34","author":"Arvanitakis","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.535","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1155\/2007\/924257","article-title":"Hospitalization-based major comorbidity of inflammatory bowel disease in Canada","volume":"21","author":"Bernstein","year":"2007","journal-title":"Can J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.536","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.02052.x"},{"key":"2026032503500973000_74.Suppl_2.s1.537","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/apt.17162","article-title":"Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis","volume":"56","author":"Faye","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.538","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.13670","article-title":"Review article: acute severe ulcerative colitis - evidence-based consensus statements","volume":"44","author":"Chen","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.539","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61963-2"},{"key":"2026032503500973000_74.Suppl_2.s1.540","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.3.328"},{"key":"2026032503500973000_74.Suppl_2.s1.541","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/ecco-jcc\/jjac112","article-title":"Venous Thromboembolism Following Discharge from Hospital in Patients Admitted for Inflammatory Bowel Disease","volume":"17","author":"Harvey","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.542","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.cgh.2019.07.028","article-title":"Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases","volume":"18","author":"Faye","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.543","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/apt.15286","article-title":"A clinical predictive model for post\u2010hospitalisation venous thromboembolism in patients with inflammatory bowel disease","volume":"49","author":"McCurdy","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.544","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/DCR.0000000000001036","article-title":"Elevated Venous Thromboembolism Risk Following Colectomy for IBD Is Equal to Those for Colorectal Cancer for Ninety Days After Surgery","volume":"61","author":"Ali","year":"2018","journal-title":"Dis Colon Rectum"},{"key":"2026032503500973000_74.Suppl_2.s1.545","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.crohns.2014.07.007","article-title":"The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease","volume":"8","author":"Nguyen","year":"2014","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.546","doi-asserted-by":"publisher","DOI":"10.1081\/IPH-200067702"},{"key":"2026032503500973000_74.Suppl_2.s1.547","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11236884","article-title":"The Effect of Anti-Tumor Necrosis Factor-Alpha Therapy within 12 Weeks Prior to Surgery on Postoperative Complications in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"11","author":"Cira","year":"2022","journal-title":"J Clin Med"},{"key":"2026032503500973000_74.Suppl_2.s1.548","doi-asserted-by":"crossref","unstructured":"Law CC , Koh D , Bao Y , et al . n.d. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database Syst Rev. doi:10.1002\/14651858.CD013256","DOI":"10.1002\/14651858.CD013256"},{"key":"2026032503500973000_74.Suppl_2.s1.549","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.201"},{"key":"2026032503500973000_74.Suppl_2.s1.550","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/MEG.0000000000001944","article-title":"Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients","volume":"33","author":"Moosvi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.551","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy156"},{"key":"2026032503500973000_74.Suppl_2.s1.552","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00384-021-04017-2","article-title":"Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis","volume":"36","author":"Guo","year":"2021","journal-title":"Int J Colorectal Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.553","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx163"},{"key":"2026032503500973000_74.Suppl_2.s1.554","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194402","article-title":"Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu","volume":"10","author":"Garc\u00eda","year":"2021","journal-title":"J Clin Med"},{"key":"2026032503500973000_74.Suppl_2.s1.555","first-page":"691","article-title":"Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn\u2019s disease: a systematic review and meta-analysis","volume":"34","author":"Garg","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.556","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000533594","article-title":"Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn\u2019s Disease Patients","volume":"64","author":"Li","year":"2023","journal-title":"Eur Surg Res"},{"key":"2026032503500973000_74.Suppl_2.s1.557","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000958"},{"key":"2026032503500973000_74.Suppl_2.s1.558","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001073"},{"key":"2026032503500973000_74.Suppl_2.s1.559","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000556"},{"key":"2026032503500973000_74.Suppl_2.s1.560","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00384-018-3105-8","article-title":"Impact of superimposed Clostridium difficile infection in Crohn\u2019s or ulcerative colitis flares in the outpatient setting","volume":"33","author":"Garcia","year":"2018","journal-title":"Int J Colorectal Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.561","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.04.044"},{"key":"2026032503500973000_74.Suppl_2.s1.562","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjy143","article-title":"Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"13","author":"Balram","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.563","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir201"},{"key":"2026032503500973000_74.Suppl_2.s1.564","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy031"},{"key":"2026032503500973000_74.Suppl_2.s1.565","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MCG.0000000000001633","article-title":"Outcomes of Fecal Microbiota Transplantation for C. difficile Infection in Inflammatory Bowel Disease\u202f: A Systematic Review and Meta-analysis","volume":"57","author":"Tariq","year":"2023","journal-title":"J Clin Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.566","doi-asserted-by":"crossref","first-page":"103036","DOI":"10.1016\/j.jaut.2023.103036","article-title":"Fecal microbiota transplantation for recurrent C. difficile infection in patients with inflammatory bowel disease: A systematic review and meta-analysis","volume":"141","author":"Porcari","year":"2023","journal-title":"J Autoimmun"},{"key":"2026032503500973000_74.Suppl_2.s1.567","article-title":"Interventions for treating iron deficiency anaemia in inflammatory bowel disease","volume":"1","author":"Gordon","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.568","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jju009"},{"key":"2026032503500973000_74.Suppl_2.s1.569","article-title":"Interventions for fatigue in inflammatory bowel disease","volume":"4","author":"Farrell","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.570","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.cgh.2016.03.018","article-title":"Preconception Care Reduces Relapse of Inflammatory Bowel Disease During Pregnancy","volume":"14","author":"de Lima","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.571","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.50"},{"key":"2026032503500973000_74.Suppl_2.s1.572","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.22574"},{"key":"2026032503500973000_74.Suppl_2.s1.573","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw078"},{"key":"2026032503500973000_74.Suppl_2.s1.574","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ajg.2016.254","article-title":"The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies","volume":"111","author":"de Lima-Karagiannis","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.575","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.022"},{"key":"2026032503500973000_74.Suppl_2.s1.576","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10620-020-06282-7","article-title":"Factors Associated with Inflammatory Bowel Disease Flare During Pregnancy Among Women with Preconception Remission","volume":"66","author":"Rottenstreich","year":"2021","journal-title":"Dig Dis Sci"},{"key":"2026032503500973000_74.Suppl_2.s1.577","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa225"},{"key":"2026032503500973000_74.Suppl_2.s1.578","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/apt.15654","article-title":"Pregnancy outcomes in women with inflammatory bowel disease: a 10-year nationwide population-based cohort study","volume":"51","author":"Lee","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.579","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22948"},{"key":"2026032503500973000_74.Suppl_2.s1.580","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCG.0000000000001244","article-title":"Noninvasive Methods For Assessing Inflammatory Bowel Disease Activity in Pregnancy: A Systematic Review","volume":"53","author":"Tandon","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.581","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejim.2020.03.015","article-title":"Clinical utility of fecal calprotectin in monitoring disease activity and predicting relapse in pregnant patients with inflammatory bowel diseases","volume":"77","author":"Rottenstreich","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2026032503500973000_74.Suppl_2.s1.582","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/codi.16098","article-title":"Pregnancy outcomes after stoma surgery for inflammatory bowel disease: The results of a retrospective multicentre audit","volume":"24","year":"2022","journal-title":"Colorectal Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.583","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and Colitis guidelines on sexuality","volume":"17","author":"Torres","year":"2023","journal-title":"Fertility, Pregnancy, and Lactation J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.584","doi-asserted-by":"crossref","first-page":"9898","DOI":"10.3748\/wjg.v22.i45.9898","article-title":"Contraindications for video capsule endoscopy","volume":"22","author":"Bandorski","year":"2016","journal-title":"World J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.585","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/ecco-jcc\/jjaa082","article-title":"Monitoring Inflammatory Bowel Disease in Pregnancy Using Gastrointestinal Ultrasonography","volume":"14","author":"Flanagan","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.586","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2007.11.010"},{"key":"2026032503500973000_74.Suppl_2.s1.587","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432204"},{"key":"2026032503500973000_74.Suppl_2.s1.588","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91443-P"},{"key":"2026032503500973000_74.Suppl_2.s1.589","doi-asserted-by":"publisher","DOI":"10.3109\/01443615.2012.716106"},{"key":"2026032503500973000_74.Suppl_2.s1.590","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cgh.2017.02.041","article-title":"Use of Thiopurines During Conception and Pregnancy Is Not Associated With Adverse Pregnancy Outcomes or Health of Infants at One Year in a Prospective Study","volume":"15","author":"Kanis","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.591","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319129"},{"key":"2026032503500973000_74.Suppl_2.s1.592","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/apt.18126","article-title":"Multicentre study and systematic review: Allopurinol exposure during pregnancy","volume":"60","author":"Crouwel","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.593","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.38368","article-title":"Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study","volume":"66","author":"Weber-Schoendorfer","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2026032503500973000_74.Suppl_2.s1.594","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20858"},{"key":"2026032503500973000_74.Suppl_2.s1.595","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200104270-00006"},{"key":"2026032503500973000_74.Suppl_2.s1.596","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0000150346.42901.07"},{"key":"2026032503500973000_74.Suppl_2.s1.597","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2017.04.013"},{"key":"2026032503500973000_74.Suppl_2.s1.598","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325317"},{"key":"2026032503500973000_74.Suppl_2.s1.599","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv006"},{"key":"2026032503500973000_74.Suppl_2.s1.600","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20640"},{"key":"2026032503500973000_74.Suppl_2.s1.601","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.71"},{"key":"2026032503500973000_74.Suppl_2.s1.602","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s40262-017-0546-0","article-title":"A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab","volume":"56","author":"Rosario","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2026032503500973000_74.Suppl_2.s1.603","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.6.17815"},{"key":"2026032503500973000_74.Suppl_2.s1.604","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.2147\/DDDT.S167149","article-title":"Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis","volume":"12","author":"Haugh","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.605","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/apt.16102","article-title":"Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure","volume":"52","author":"Flanagan","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.606","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/apt.16739","article-title":"Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero","volume":"55","author":"Flanagan","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.607","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.11.011"},{"key":"2026032503500973000_74.Suppl_2.s1.608","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2013.812141","article-title":"Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-\u03b1 therapy during pregnancy: three-center study","volume":"48","author":"Bortlik","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.609","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.10.024"},{"key":"2026032503500973000_74.Suppl_2.s1.610","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/apt.16593","article-title":"Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study","volume":"54","author":"Julsgaard","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.611","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.002"},{"key":"2026032503500973000_74.Suppl_2.s1.612","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.613","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309321"},{"key":"2026032503500973000_74.Suppl_2.s1.614","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0176-7"},{"key":"2026032503500973000_74.Suppl_2.s1.615","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","article-title":"The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.616","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv234"},{"key":"2026032503500973000_74.Suppl_2.s1.617","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.501"},{"key":"2026032503500973000_74.Suppl_2.s1.618","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1093\/rheumatology\/keac141","article-title":"A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero","volume":"61","author":"Goulden","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026032503500973000_74.Suppl_2.s1.619","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2352-4642(23)00136-0","article-title":"Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network","volume":"7","author":"Fitzpatrick","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"2026032503500973000_74.Suppl_2.s1.620","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jgh.15574","article-title":"Systematic review and meta-analysis: Safety of vedolizumab during pregnancy in patients with inflammatory bowel disease","volume":"36","author":"Bell","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.621","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15539"},{"key":"2026032503500973000_74.Suppl_2.s1.622","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.623","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.14309\/ajg.0000000000000186","article-title":"Exposure to Vedolizumab in IBD Pregnant Women Appears of Low Risk for Mother and Neonate: A First Prospective Comparison Study","volume":"114","author":"Bar-Gil Shitrit","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.624","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy160"},{"key":"2026032503500973000_74.Suppl_2.s1.625","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1093\/ibd\/izae011","article-title":"Pregnancy Outcomes in the Ozanimod Clinical Development Program in Patients With Ulcerative Colitis, Crohn\u2019s Disease, and Relapsing Multiple Sclerosis","volume":"30","author":"Dubinsky","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.626","doi-asserted-by":"crossref","unstructured":"Cornish J , Tan E , Teare J . No title. Gut 2007;56. doi:10.1136\/gut.2006.108324","DOI":"10.1136\/gut.2006.108324"},{"key":"2026032503500973000_74.Suppl_2.s1.627","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0b013e3182a41381"},{"key":"2026032503500973000_74.Suppl_2.s1.628","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/MIB.0000000000001112","article-title":"Defining the Most Appropriate Delivery Mode in Women with Inflammatory Bowel Disease: A Systematic Review","volume":"23","author":"Foulon","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.629","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-005-0124-7"},{"key":"2026032503500973000_74.Suppl_2.s1.630","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.02.011"},{"key":"2026032503500973000_74.Suppl_2.s1.631","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1097\/MIB.0000000000000207","article-title":"Abdominal pain and the neurotrophic system in ulcerative colitis","volume":"20","author":"Deberry","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.632","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201410002-01650","article-title":"Causes and Consequences of Chronic Abdominal Pain in Crohn\u2019s Disease: A Five-Year Prospective Study","volume":"109","author":"Seth","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.633","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i25.3168"},{"key":"2026032503500973000_74.Suppl_2.s1.634","doi-asserted-by":"publisher","DOI":"10.1007\/s10880-008-9132-9"},{"key":"2026032503500973000_74.Suppl_2.s1.635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156666","article-title":"Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account","volume":"11","author":"Zeitz","year":"2016","journal-title":"PLoS One"},{"key":"2026032503500973000_74.Suppl_2.s1.636","unstructured":"Boyle M , Murphy S , Leyden J . Analysis of patient perception of pain and management strategies in IBD. JOURNAL OF CROHNS & COLITIS; 2015: OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND 2015."},{"key":"2026032503500973000_74.Suppl_2.s1.637","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e31829614c6"},{"key":"2026032503500973000_74.Suppl_2.s1.638","doi-asserted-by":"publisher","DOI":"10.1097\/SGA.0000000000000055"},{"key":"2026032503500973000_74.Suppl_2.s1.639","doi-asserted-by":"crossref","first-page":"674","DOI":"10.3109\/00365521.2014.898084","article-title":"Prevalence of irritable bowel syndrome-like symptoms in ulcerative colitis patients with clinical and endoscopic evidence of remission: prospective multicenter study","volume":"49","author":"Fukuba","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.640","doi-asserted-by":"publisher","DOI":"10.1080\/08870446.2012.691169"},{"key":"2026032503500973000_74.Suppl_2.s1.641","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2468-1253(16)30206-0","article-title":"Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis","volume":"2","author":"Gracie","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.642","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(87)90043-1"},{"key":"2026032503500973000_74.Suppl_2.s1.643","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05466-4","article-title":"Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency\/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial","volume":"22","author":"Norton","year":"2021","journal-title":"Trials"},{"key":"2026032503500973000_74.Suppl_2.s1.644","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324598"},{"key":"2026032503500973000_74.Suppl_2.s1.645","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-305191"},{"key":"2026032503500973000_74.Suppl_2.s1.646","doi-asserted-by":"publisher","DOI":"10.1016\/S0005-7967(03)00146-3"},{"key":"2026032503500973000_74.Suppl_2.s1.647","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000437614.91258.70"},{"key":"2026032503500973000_74.Suppl_2.s1.648","doi-asserted-by":"crossref","first-page":"39","DOI":"10.12968\/gasn.2016.14.8.39","article-title":"The effect of increasing physical activity and\/or omega-3 supplementation on fatigue in inflammatory bowel disease","volume":"14","author":"McNelly","year":"2016","journal-title":"Gastrointestinal Nursing"},{"key":"2026032503500973000_74.Suppl_2.s1.649","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz091"},{"key":"2026032503500973000_74.Suppl_2.s1.650","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(13)62634-7"},{"key":"2026032503500973000_74.Suppl_2.s1.651","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00365521.2021.1983640","article-title":"Long-term maintenance treatment with 300\u2009mg thiamine for fatigue in patients with inflammatory bowel disease: results from an open-label extension of the TARIF study","volume":"57","author":"Bager","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.652","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30300-3"},{"key":"2026032503500973000_74.Suppl_2.s1.653","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.046615"},{"key":"2026032503500973000_74.Suppl_2.s1.654","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL Clinical Practice Guidelines on sclerosing cholangitis","volume":"77","author":"Chazouilleres","year":"2022","journal-title":"J Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.655","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.08.039"},{"key":"2026032503500973000_74.Suppl_2.s1.656","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.657","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.3748\/wjg.14.3974","article-title":"Primary sclerosing cholangitis - What is the difference between east and west?","volume":"14","author":"Shorbagi","year":"2008","journal-title":"WJG"},{"key":"2026032503500973000_74.Suppl_2.s1.658","doi-asserted-by":"publisher","DOI":"10.1080\/00365520801977568"},{"key":"2026032503500973000_74.Suppl_2.s1.659","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318196d018"},{"key":"2026032503500973000_74.Suppl_2.s1.660","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-010-0319-8"},{"key":"2026032503500973000_74.Suppl_2.s1.661","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e3182802893"},{"key":"2026032503500973000_74.Suppl_2.s1.662","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i6.1956"},{"key":"2026032503500973000_74.Suppl_2.s1.663","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i5.445"},{"key":"2026032503500973000_74.Suppl_2.s1.664","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21699"},{"key":"2026032503500973000_74.Suppl_2.s1.665","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2697-7"},{"key":"2026032503500973000_74.Suppl_2.s1.666","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cgh.2017.07.023","article-title":"Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon","volume":"16","author":"Krugliak Cleveland","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.667","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.22938"},{"key":"2026032503500973000_74.Suppl_2.s1.668","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317993"},{"key":"2026032503500973000_74.Suppl_2.s1.669","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314924"},{"key":"2026032503500973000_74.Suppl_2.s1.670","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.235408"},{"key":"2026032503500973000_74.Suppl_2.s1.671","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01333.x"},{"key":"2026032503500973000_74.Suppl_2.s1.672","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/830291"},{"key":"2026032503500973000_74.Suppl_2.s1.673","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/0016-5085(92)90308-L","article-title":"Primary sclerosing cholangitis in ulcerative colitis\u2014A risk factor for the development of dysplasia and DNA aneuploidy?","volume":"102","author":"Broom\u00e9","year":"1992","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.674","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease","volume":"28","author":"Zheng","year":"2016","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"2026032503500973000_74.Suppl_2.s1.675","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.676","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0b013e31822bbcc1"},{"key":"2026032503500973000_74.Suppl_2.s1.677","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.10.020"},{"key":"2026032503500973000_74.Suppl_2.s1.678","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/apt.14828","article-title":"The impact of ileal pouch\u2010anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis","volume":"48","author":"Trivedi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.679","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/SLA.0000000000006041","article-title":"Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis-inflammatory Bowel Disease (PSC-IBD)","volume":"278","author":"Maspero","year":"2023","journal-title":"Ann Surg"},{"key":"2026032503500973000_74.Suppl_2.s1.680","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ecco-jcc\/jjaa195","article-title":"Impact of an Education Programme on IBD Patients\u2019 Skills: Results of a Randomised Controlled Multicentre Study [ECIPE]","volume":"15","author":"Moreau","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.681","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000452989","article-title":"Beneficial Effects of Education on Emotional Distress, Self-Management, and Coping in Patients with Inflammatory Bowel Disease: A Prospective Randomized Controlled Study","volume":"1","author":"Berding","year":"2017","journal-title":"Inflamm Intest Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.682","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab232.851","article-title":"N09 Disease knowledge and quality of life perception in Inflammatory Bowel Disease: a randomised controlled trial","volume":"16","author":"Martinato","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.683","first-page":"415","article-title":"The effect of web-based education on disease activity, symptom management and quality of life in patients with inflammatory bowel disease: randomized-controlled study","volume":"23","author":"Uran","year":"2019","journal-title":"Med Sci"},{"key":"2026032503500973000_74.Suppl_2.s1.684","doi-asserted-by":"crossref","first-page":"S560","DOI":"10.1093\/ecco-jcc\/jjy222.997","article-title":"N09 IBD nurse intervention for patients assigned to biologic therapy decreases uncertainty and improves patient-reported outcomes","volume":"13","author":"Barkan","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.685","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-63168-4","article-title":"The effect of a mindfulness-based therapy on different biomarkers among patients with inflammatory bowel disease: a randomised controlled trial","volume":"10","author":"Gonz\u00e1lez-Moret","year":"2020","journal-title":"Sci Rep"},{"key":"2026032503500973000_74.Suppl_2.s1.686","first-page":"634","article-title":"Comprehensive lifestyle-modification including multi -Modal stress management techniques in patients with ulcerative colitis - results of a randomized controlled trial and the Trier social stress test","volume":"7","author":"Langhorst","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"2026032503500973000_74.Suppl_2.s1.687","doi-asserted-by":"crossref","DOI":"10.1111\/ijn.12699","article-title":"Cognitive-behavioural therapy in patients with inflammatory bowel diseases: A systematic review and meta-analysis","volume":"25","author":"Li","year":"2019","journal-title":"Int J Nurs Pract"},{"key":"2026032503500973000_74.Suppl_2.s1.688","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/ecco-jcc\/jjx062","article-title":"Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence","volume":"11","author":"Nikolaus","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.689","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/MPG.0000000000002431","article-title":"Evaluation of a Novel Educational Tool in Adolescents With Inflammatory Bowel Disease: The NEAT Study","volume":"69","author":"Vaz","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026032503500973000_74.Suppl_2.s1.690","doi-asserted-by":"crossref","first-page":"349","DOI":"10.5217\/ir.2018.00064","article-title":"Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study","volume":"17","author":"Park","year":"2019","journal-title":"Intest Res"},{"key":"2026032503500973000_74.Suppl_2.s1.691","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.pec.2021.10.017","article-title":"Interventions to improve medication adherence in inflammatory bowel disease: A systematic review","volume":"105","author":"Gohil","year":"2022","journal-title":"Patient Educ Couns"},{"key":"2026032503500973000_74.Suppl_2.s1.692","doi-asserted-by":"crossref","first-page":"78","DOI":"10.14309\/ajg.0000000000001545","article-title":"Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review","volume":"117","author":"Nguyen","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.693","article-title":"Patient education interventions for the management of inflammatory bowel disease","volume":"5","author":"Gordon","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032503500973000_74.Suppl_2.s1.694","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313000"},{"key":"2026032503500973000_74.Suppl_2.s1.695","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/ecco-jcc\/jjx010","article-title":"European Crohn\u2019s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease","volume":"11","author":"van Rheenen","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.696","first-page":"331","article-title":"Spotlight on Transition in Patients With Inflammatory Bowel Disease: A Systematic Review","volume":"26","author":"Er\u0151s","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.697","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02424.x"},{"key":"2026032503500973000_74.Suppl_2.s1.698","first-page":"22","article-title":"Smoking cessation: What should you recommend?","volume":"65","author":"Bornemann","year":"2016","journal-title":"J Fam Pract"},{"key":"2026032503500973000_74.Suppl_2.s1.699","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000309","article-title":"Current smoking habits in British IBD patients in the age of e-cigarettes","volume":"6","author":"Chong","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.700","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s10620-022-07539-z","article-title":"E-cigarette Use and Disease Outcomes in Inflammatory Bowel Diseases: A Case-Control Study","volume":"68","author":"Sheehan","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2026032503500973000_74.Suppl_2.s1.701","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2023.04.014"},{"key":"2026032503500973000_74.Suppl_2.s1.702","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13511"},{"key":"2026032503500973000_74.Suppl_2.s1.703","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200501000-00006"},{"key":"2026032503500973000_74.Suppl_2.s1.704","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13239"},{"key":"2026032503500973000_74.Suppl_2.s1.705","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(03)00290-8"},{"key":"2026032503500973000_74.Suppl_2.s1.706","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-008-0542-9"},{"key":"2026032503500973000_74.Suppl_2.s1.707","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjsurg.2014.10.033","article-title":"Smoking as dominant risk factor for anastomotic leak after left colon resection","volume":"210","author":"Baucom","year":"2015","journal-title":"The American Journal of Surgery"},{"key":"2026032503500973000_74.Suppl_2.s1.708","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182708cc5"},{"key":"2026032503500973000_74.Suppl_2.s1.709","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20884"},{"key":"2026032503500973000_74.Suppl_2.s1.710","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1016\/j.crohns.2013.05.007","article-title":"Crohn\u2019s disease and smoking: Is it ever too late to quit?","volume":"7","author":"Lawrance","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.711","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/MEG.0000000000000371","article-title":"Beliefs and behaviour about smoking among inflammatory bowel disease patients","volume":"27","author":"Saadoune","year":"2015","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"2026032503500973000_74.Suppl_2.s1.712","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13423"},{"key":"2026032503500973000_74.Suppl_2.s1.713","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/ecco-jcc\/jjv113","article-title":"High Rates of Smoking Especially in Female Crohn\u2019s Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation\u2014Data from the Swiss IBD Cohort Study","volume":"9","author":"Biedermann","year":"2015","journal-title":"ECCOJC"},{"key":"2026032503500973000_74.Suppl_2.s1.714","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.300"},{"key":"2026032503500973000_74.Suppl_2.s1.715","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.crohns.2012.04.011","article-title":"High smoking cessation rate in Crohn\u2019s disease patients after physician advice \u2013 The TABACROHN Study","volume":"7","author":"Nunes","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.716","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jgh.12616","article-title":"Second peak in the distribution of age at onset of ulcerative colitis in relation to smoking cessation","volume":"29","author":"Takahashi","year":"2014","journal-title":"J of Gastro and Hepatol"},{"key":"2026032503500973000_74.Suppl_2.s1.717","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/ajg.2012.190","article-title":"The truth about cigarette smoking and the risk of inflammatory bowel disease","volume":"107","author":"Rosenfeld","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.718","doi-asserted-by":"publisher","DOI":"10.1007\/BF01648362"},{"key":"2026032503500973000_74.Suppl_2.s1.719","doi-asserted-by":"publisher","DOI":"10.1007\/BF00299330"},{"key":"2026032503500973000_74.Suppl_2.s1.720","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.12.010"},{"key":"2026032503500973000_74.Suppl_2.s1.721","doi-asserted-by":"publisher","DOI":"10.1080\/00365520500527482"},{"key":"2026032503500973000_74.Suppl_2.s1.722","doi-asserted-by":"crossref","first-page":"S052","DOI":"10.1093\/ecco-jcc\/jjx180.068","article-title":"DOP031 Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practice","volume":"12","author":"Ankersen","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.723","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.678"},{"key":"2026032503500973000_74.Suppl_2.s1.724","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31327-2"},{"key":"2026032503500973000_74.Suppl_2.s1.725","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0272-8"},{"key":"2026032503500973000_74.Suppl_2.s1.726","doi-asserted-by":"crossref","DOI":"10.2196\/11602","article-title":"A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial","volume":"20","author":"Del Hoyo","year":"2018","journal-title":"J Med Internet Res"},{"key":"2026032503500973000_74.Suppl_2.s1.727","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/ibd\/izz252","article-title":"A Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients","volume":"26","author":"McCombie","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.728","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10122709","article-title":"The Use of Virtual Reality to Reduce Stress among Inflammatory Bowel Disease Patients Treated with Vedolizumab","volume":"10","author":"Lewandowski","year":"2021","journal-title":"J Clin Med"},{"key":"2026032503500973000_74.Suppl_2.s1.729","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1093\/ibd\/izaa024","article-title":"Use of an iPhone Application to Increase Adherence in Patients With Ulcerative Colitis in Remission: A Randomized Controlled Trial","volume":"26","author":"Ley","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.730","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.21037\/apm-21-1056","article-title":"Effect of probiotics supplementation combined with WeChat platform health management on nutritional status, inflammatory factors, and quality of life in patients with mild-to-moderate ulcerative colitis: a randomized trial","volume":"10","author":"Ou","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2026032503500973000_74.Suppl_2.s1.731","doi-asserted-by":"crossref","DOI":"10.1093\/crocol\/otaa002","article-title":"TELEmedicine for Patients With Inflammatory Bowel Disease (TELE-IBD) Does Not Improve Depressive Symptoms or General Quality of Life Compared With Standard Care at Tertiary Referral Centers","volume":"2","author":"Schliep","year":"2020","journal-title":"Crohns Colitis 360"},{"key":"2026032503500973000_74.Suppl_2.s1.732","doi-asserted-by":"crossref","unstructured":"Gordon M , Sinopoulou V , Lakunina S , et al . n.d. Remote care through telehealth for people with inflammatory bowel disease. Cochrane Database Syst Rev 2023. doi:10.1002\/14651858.CD014821.pub2","DOI":"10.1002\/14651858.CD014821.pub2"},{"key":"2026032503500973000_74.Suppl_2.s1.733","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/ecco-jcc\/jjad075","article-title":"Management of Inflammatory Bowel Disease Using E-health Technologies: A Systematic Review and Meta-Analysis","volume":"17","author":"Kuriakose Kuzhiyanjal","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.734","doi-asserted-by":"crossref","first-page":"i1494","DOI":"10.1093\/ecco-jcc\/jjad212.0931","article-title":"P801 Umbrella review of effectiveness of digital technologies for the management of Inflammatory Bowel Disease","volume":"18","author":"Gasparetto","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.735","doi-asserted-by":"publisher","DOI":"10.7861\/futurehosp.15.016"},{"key":"2026032503500973000_74.Suppl_2.s1.736","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jpn3.12105","article-title":"Top 10 research priorities for digital technology for adolescents and young persons with inflammatory bowel disease: Results of a James Lind Alliance Priority Setting Partnership","volume":"78","author":"Narula","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2026032503500973000_74.Suppl_2.s1.737","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1093\/rheumatology\/keac295","article-title":"The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs","volume":"61","author":"Tucker","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026032503500973000_74.Suppl_2.s1.738","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223296"},{"key":"2026032503500973000_74.Suppl_2.s1.739","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/ecco-jcc\/jjac058","article-title":"The Impact of Vedolizumab and Ustekinumab on Articular Extra-Intestinal Manifestations in Inflammatory Bowel Disease Patients: A Real-Life Multicentre Cohort Study","volume":"16","author":"De Galan","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.740","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ibd\/izaa293","article-title":"The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study","volume":"27","author":"Ramos","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.741","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/rheumatology\/key267","article-title":"Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease","volume":"58","author":"Dubash","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026032503500973000_74.Suppl_2.s1.742","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of Arthritis\/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials","volume":"13","author":"Feagan","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.743","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"2026032503500973000_74.Suppl_2.s1.744","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217927"},{"key":"2026032503500973000_74.Suppl_2.s1.745","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"2026032503500973000_74.Suppl_2.s1.746","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.027"},{"key":"2026032503500973000_74.Suppl_2.s1.747","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"2026032503500973000_74.Suppl_2.s1.748","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.010"},{"key":"2026032503500973000_74.Suppl_2.s1.749","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.12.032"},{"key":"2026032503500973000_74.Suppl_2.s1.750","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","article-title":"Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA","volume":"61","author":"O\u2019Toole","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2026032503500973000_74.Suppl_2.s1.751","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/art.41923","article-title":"Risk of Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis\/Ankylosing Spondylitis Initiating Interleukin-17 Inhibitors: A Nationwide Population-Based Study Using the French National Health Data System","volume":"74","author":"Penso","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026032503500973000_74.Suppl_2.s1.752","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.847160","article-title":"Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"2026032503500973000_74.Suppl_2.s1.753","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.06.005"},{"key":"2026032503500973000_74.Suppl_2.s1.754","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200403000-00012"},{"key":"2026032503500973000_74.Suppl_2.s1.755","first-page":"675","article-title":"Review: Ocular side effects of anti-rheumatic medications: what a rheumatologist should know","volume":"19","author":"Peponis","year":"2010","journal-title":"Lupus (Los Angel)"},{"key":"2026032503500973000_74.Suppl_2.s1.756","doi-asserted-by":"crossref","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2026032503500973000_74.Suppl_2.s1.757","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajoc.2022.101331","article-title":"A case of ustekinumab-induced sclerouveitis","volume":"25","author":"Godwin","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2026032503500973000_74.Suppl_2.s1.758","unstructured":"Department of Health . Polio: the green book, chapter 26. 2013."},{"key":"2026032503500973000_74.Suppl_2.s1.759","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/j.1572-0241.2008.02103.x","article-title":"Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study","volume":"103","author":"Bossa","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"2026032503500973000_74.Suppl_2.s1.760","unstructured":"Reflexivity: a challenge for the researcher as practitioner. 2006."},{"key":"2026032503500973000_74.Suppl_2.s1.761","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01609.x"},{"key":"2026032503500973000_74.Suppl_2.s1.762","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01298.x"},{"key":"2026032503500973000_74.Suppl_2.s1.763","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"2026032503500973000_74.Suppl_2.s1.764","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026032503500973000_74.Suppl_2.s1.765","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/ibd\/izab143","article-title":"Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study","volume":"28","author":"Hanzel","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.766","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00068-9"},{"key":"2026032503500973000_74.Suppl_2.s1.767","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"The Lancet"},{"key":"2026032503500973000_74.Suppl_2.s1.768","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2018.06.30","article-title":"DIAMOND study: an additional evidence of the interest of being proactive in IBD","volume":"6","author":"Roblin","year":"2018","journal-title":"Ann Transl Med"},{"key":"2026032503500973000_74.Suppl_2.s1.769","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ibd\/izab259","article-title":"Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn\u2019s Disease","volume":"28","author":"Hanzel","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026032503500973000_74.Suppl_2.s1.770","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i3.1078"},{"key":"2026032503500973000_74.Suppl_2.s1.771","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(95)90121-3"},{"key":"2026032503500973000_74.Suppl_2.s1.772","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.010"},{"key":"2026032503500973000_74.Suppl_2.s1.773","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-4731(75)90125-9","article-title":"Mechanism of action of steroid hormones","volume":"6","author":"Edelman","year":"1975","journal-title":"J Steroid Biochem"},{"key":"2026032503500973000_74.Suppl_2.s1.774","unstructured":"Committee JF . British national formulary. Pharmaceutical Press, 2012."},{"key":"2026032503500973000_74.Suppl_2.s1.775","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2036.18.s2.1.x","article-title":"Review article: mechanisms of action of Mesalazine in preventing colorectal carcinoma in inflammatory bowel disease","volume":"18 Suppl 2","author":"Allgayer","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032503500973000_74.Suppl_2.s1.776","first-page":"RA247","article-title":"Reviewing the mechanism of action of Thiopurine drugs: towards a new paradigm in clinical practice","volume":"10","author":"Cara","year":"2004","journal-title":"Med Sci Monit"},{"key":"2026032503500973000_74.Suppl_2.s1.777","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw053"},{"key":"2026032503500973000_74.Suppl_2.s1.778","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0373-9"},{"key":"2026032503500973000_74.Suppl_2.s1.779","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2023-100012","article-title":"Horizon scanning: new and future therapies in the management of inflammatory bowel disease","volume":"1","author":"Kumar","year":"2023","journal-title":"eGastroenterology"},{"key":"2026032503500973000_74.Suppl_2.s1.780","unstructured":"Gynaecologists RCoOa . Reducing the risk of thrombosis and embolism during pregnancy and the Puerperium. Green-Top Guideline 2015."},{"key":"2026032503500973000_74.Suppl_2.s1.781","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2020-101459"}],"updated-by":[{"DOI":"10.1136\/gutjnl-2024-334395corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000}}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2024-334395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:51:17Z","timestamp":1774435877000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2024-334395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":781,"journal-issue":{"issue":"Suppl 2","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/gutjnl-2024-334395"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2024-334395","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}